http://cancerGRACE.org
We interview patients, advocates and healthcare professionals to provide the most updated information for our community and to highlight important issues facing those dealing with a cancer diagnosis.

For more information visit www.cancerGRACE.org. To join the conversation, visit https://cancergrace.org/forums]]>enMedicineCopyright cancerGRACEhttps://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/df7f5e3e667a5a4883a1847aa678ff4d.jpghttp://cancerGRACE.orgWed, 13 May 2026 08:00:15 +0000cancerGRACEcancerGRACEinfo@cancergrace.orgIn this podcast series, the Global Resource for Advancing Cancer Education (GRACE) works to bring professionals together with patients and caregivers to work in partnership. We interview patients, advocates and healthcare professionals to provide...
We interview patients, advocates and healthcare professionals to provide the most updated information for our community and to highlight important issues facing those dealing with a cancer diagnosis.

For more information visit www.cancerGRACE.org. To join the conversation, visit https://cancergrace.org/forums]]>false3bde4f03-ad6f-5923-b7e6-e1d497b3fe17episodichttps://www.spreaker.com/episode/treatment-options-for-pancreatic-cancer-gastrointestinal-cancers-oncinsights-2025-26--69576535https://api.spreaker.com/episode/69576535Wed, 13 May 2026 08:00:02 +0000cancerGRACEDr. Steven Bialick discusses treatment options for pancreatic cancer.388cancer,options,pancreatic,treatmentfalsefullhttps://www.spreaker.com/episode/symptoms-of-pancreatic-cancer-gastrointestinal-cancers-oncinsights-2025-26--69576534https://api.spreaker.com/episode/69576534Wed, 06 May 2026 08:00:02 +0000cancerGRACEDr. Steven Bialick discusses the various symptoms that may be present with pancreatic cancer.164cancer,pancreatic,symptomsfalsefullhttps://www.spreaker.com/episode/diagnostic-lab-tests-in-pancreatic-cancer-gastrointestinal-cancers-oncinsights-2025-26--69576533https://api.spreaker.com/episode/69576533Wed, 29 Apr 2026 08:00:02 +0000cancerGRACEDr. Steven Bialick discusses the types of lab tests done on patients with suspected pancreatic cancer, including CBC, CMP, CEA, and CA19-9.220ca19-9,cancer,cbc,cea,cmp,diagnostic,lab,pancreatic,testsfalsefullhttps://www.spreaker.com/episode/genetic-testing-in-pancreatic-cancer-gastrointestinal-cancers-oncinsights-2025-26--69576532https://api.spreaker.com/episode/69576532Wed, 22 Apr 2026 08:00:02 +0000cancerGRACEDr. Steven Bialick discusses genetic testing in pancreatic cancer, including the difference in germline and somatic testing, and which mutations may have known treatments.382cancer,genetic,germline,pancreatic,somatic,testingfalsefullhttps://www.spreaker.com/episode/understanding-nccn-guidelines-in-pancreatic-cancer-gastrointestinal-cancers-oncinsights-2025-26--69576531https://api.spreaker.com/episode/69576531Wed, 22 Apr 2026 08:00:02 +0000cancerGRACEDr. Steven Bialick discusses the NCCN guidelines for diagnosing pancreatic cancer, as well as the various members of a patient's care team.253cancer,guidelines,nccn,pancreaticfalsefullhttps://www.spreaker.com/episode/risk-factors-for-pancreatic-cancer-gastrointestinal-cancers-oncinsights-2025-26--69576530https://api.spreaker.com/episode/69576530Wed, 15 Apr 2026 08:00:02 +0000cancerGRACEDr. Steven Bialick discusses the main risk factors for pancreatic, including high BMI, smoking, and alcohol abuse.118abuse,alcohol,bmi,cancer,factors,high,pancreatic,risk,smokingfalsefullhttps://www.spreaker.com/episode/epidemiology-of-pancreatic-cancer-gastrointestinal-cancers-oncinsights-2025-26--69576529https://api.spreaker.com/episode/69576529Wed, 08 Apr 2026 09:00:10 +0000cancerGRACEDr. Steven Bialick discusses how pancreatic cancer rates are increasing, and overall patterns of diagnosis.182cancer,epidemiology,pancreaticfalsefullhttps://www.spreaker.com/episode/pancreatic-cancer-anatomy-gastrointestinal-cancers-oncinsights-2025-26--69576528https://api.spreaker.com/episode/69576528Wed, 01 Apr 2026 08:00:02 +0000cancerGRACEDr. Steven Bialick discusses the anatomy of pancreas cancer, including why a person may experience weight loss.358anatomy,cancer,pancreatic,weightlossfalsefullhttps://www.spreaker.com/episode/staging-and-prognosis-in-pancreatic-cancer-gastrointestinal-cancers-oncinsights-2025-26--69576527https://api.spreaker.com/episode/69576527Wed, 25 Mar 2026 08:00:03 +0000cancerGRACEDr. Steven Bialick discusses how location and stage affect prognosis in pancreatic cancer.237cancer,gastrointestinal,pancreatic,prognosis,stagingfalsefullhttps://www.spreaker.com/episode/diagnostic-imaging-in-pancreatic-cancer-gastrointestinal-cancers-oncinsights-2025-26--69576526https://api.spreaker.com/episode/69576526Wed, 18 Mar 2026 08:00:02 +0000cancerGRACEDr. Steven Bialick discusses the types of imaging tests used in diagnosing pancreatic cancer, including CT and PET scans.271cancer,cancers,ct,diagnostic,gastrointestinal,imaging,pancreatic,petfalsefullhttps://www.spreaker.com/episode/advanced-basal-cell-carcinoma--68449727https://api.spreaker.com/episode/68449727Wed, 11 Mar 2026 08:00:02 +0000cancerGRACEDr. Fiorinda Muhaj discusses advanced BCC, and systemic therapy options for treatment.162advanced,basal,bcc,carcinoma,cellfalsefullhttps://www.spreaker.com/episode/management-of-high-risk-basal-cell-carcinoma--68449726https://api.spreaker.com/episode/68449726Wed, 04 Mar 2026 09:00:02 +0000cancerGRACEDr. Fiorinda Muhaj discusses the management of high-risk BCC.271basal,carcinoma,cell,high-risk,managementfalsefullhttps://www.spreaker.com/episode/management-of-low-risk-basal-cell-carcinoma--68449725https://api.spreaker.com/episode/68449725Tue, 24 Feb 2026 21:15:05 +0000cancerGRACEDr. Fiorinda Muhaj discusses the management of low-risk BCC.496basal,bcc,carcinoma,cell,low-risk,managementfalsefullhttps://www.spreaker.com/episode/skin-cancer-treatment-for-non-surgical-candidates--68449724https://api.spreaker.com/episode/68449724Wed, 18 Feb 2026 09:00:02 +0000cancerGRACEDr. Vernon Sondak discusses alternatives for non-surgical candidates with skin cancer, including systemic therapy.201cancer,non-surgical,skin,treatmentfalsefullhttps://www.spreaker.com/episode/basal-cell-carcinoma-risk-factors-and-diagnosis--68449723https://api.spreaker.com/episode/68449723Wed, 11 Feb 2026 09:00:02 +0000cancerGRACEDr. Fiorinda Muhaj discusses the risk factors for developing BCC, and how it is diagnosed.348basal,bcc,carcinoma,cell,diagnosis,riskfalsefullhttps://www.spreaker.com/episode/systemic-therapy-for-skin-cancer--68449721https://api.spreaker.com/episode/68449721Wed, 04 Feb 2026 09:00:07 +0000cancerGRACEDr. Vernon Sondak discusses the recent developments in systemic therapy to treat patients with skin cancer.467cancer,skin,systemic,therapyfalsefullhttps://www.spreaker.com/episode/should-i-have-mohs-surgery--68449720https://api.spreaker.com/episode/68449720Mon, 26 Jan 2026 19:45:30 +0000cancerGRACEDr. Vernon Sondak discusses potential downsides to Mohs surgery, and why not all patients will go that route. 307cancer,melanoma,mohs,skin,surgeryfalsefullhttps://www.spreaker.com/episode/melanoma-warning-signs-and-risk-management--68449719https://api.spreaker.com/episode/68449719Sun, 04 Jan 2026 22:35:08 +0000cancerGRACEDr. Vernon Sondak gives a brief overview of melanoma, and what warning signs to look for. He also gives important information regarding skin cancer prevention overall.639management,melanoma,risk,signs,warningfalsefullhttps://www.spreaker.com/episode/follow-up-and-prevention-for-basal-cell-carcinoma--68449718https://api.spreaker.com/episode/68449718Sun, 28 Dec 2025 22:35:07 +0000cancerGRACEDr. Fiorinda Muhaj discusses how patients with BCC can follow up after treatment, and how to help prevent future BCC occurrences.166basal,carcinoma,cell,prevention,treatmentfalsefullhttps://www.spreaker.com/episode/utilizing-mohs-surgery-for-skin-cancer-treatment--68449716https://api.spreaker.com/episode/68449716Sun, 07 Dec 2025 22:30:07 +0000cancerGRACEDr. Vernon Sondak explains what Mohs surgery is, and why it may be preferable in some cases.407cancer,mohs,skin,surgery,treatmentfalsefullhttps://www.spreaker.com/episode/basal-and-squamous-cell-carcinoma-an-overview--68449715https://api.spreaker.com/episode/68449715Mon, 01 Dec 2025 22:00:08 +0000cancerGRACEDr. Vernon Sondak discusses two common types of skin cancer: basal and squamous cell. He details their characteristics and statistics.514basal,carcinoma,cell,squamousfalsefullhttps://www.spreaker.com/episode/skin-cancer-facts-and-figures--68449722https://api.spreaker.com/episode/68449722Thu, 06 Nov 2025 17:26:12 +0000cancerGRACEDr. Vernon Sondak explains the basics of skin cancer facts: how prominent it is, who is at risk, and what it can look like.299falsefullhttps://www.spreaker.com/episode/trials-in-egfr-mutated-nsclc-flaura2-and-mariposa-2024-leading-developments-in-lung-cancer--63169445https://api.spreaker.com/episode/63169445Wed, 05 Mar 2025 20:00:07 +0000cancerGRACEDrs. Desai and Abu Rous discuss trial data from Flaura2 and Mariposa as presented at 2024 ASCO, and the implications in treating EGFR+ NSCLC.6532024,asco,desai,egfr+,flaura2,in,mariposa,nsclc,rous,treating,trialfalsefullhttps://www.spreaker.com/episode/trials-in-alk-nsclc-the-crown-study-2024-leading-developments-in-lung-cancer--63169414https://api.spreaker.com/episode/63169414Wed, 26 Feb 2025 20:00:07 +0000cancerGRACEDrs. Desai and Abu Rous discuss the Crown study data as presented at ASCO 2024, and its implications in treating ALK+ NSCLC.2272024,alk+,asco,crown,data,desai,nsclc,rous,studyfalsefullhttps://www.spreaker.com/episode/limited-stage-small-cell-lung-cancer-the-adriatic-study-2024-leading-developments-in-lung-cancer--63169413https://api.spreaker.com/episode/63169413Wed, 19 Feb 2025 20:00:07 +0000cancerGRACEDrs. Desai and Abu Rous discuss the  data, as presented at ASCO 2024, and how it may change the field of treatment for limited stage small Adriatic Studycell lung cancer.2622024,adriatic,asco,cancer,cell,data,desai,limited,lung,rous,small,stage,study,treatmentfalsefullhttps://www.spreaker.com/episode/trials-in-egfr-mutated-nsclc-mariposa2-and-laura-2024-leading-developments-in-lung-cancer--63169411https://api.spreaker.com/episode/63169411Wed, 12 Feb 2025 20:00:07 +0000cancerGRACEDrs. Desai and Abu Rous discuss trial date from Mariposa2 and Laura as presented at 2024 ASCO, and the implications in treating EGFR+ NSCLC.386falsefullhttps://www.spreaker.com/episode/tarlatamab-for-extensive-stage-small-cell-lung-cancer-2024-leading-developments-in-lung-cancer--63169410https://api.spreaker.com/episode/63169410Fri, 07 Feb 2025 19:15:03 +0000cancerGRACEDrs. Desai and Abu Rous discuss using tarlatamab in treating extensive stage small cell lung cancer.421falsefullhttps://www.spreaker.com/episode/staging-skin-cancer--68449717https://api.spreaker.com/episode/68449717Thu, 30 Jan 2025 09:00:00 +0000cancerGRACEDr. Vernon Sondak discusses what factors go into the decision on staging skin cancer, including the various guidelines that different doctors may use.395cancer,skin,stagingfalsefullhttps://www.spreaker.com/episode/advances-in-thyroid-cancer-treatment--59490744https://api.spreaker.com/episode/59490744Thu, 29 Aug 2024 15:00:01 +0000cancerGRACEDrs. Patel, Sheth, and Weiss discuss emerging data and advances in thyroid cancer treatment.601advances,cancer,thyroid,treatmentfalsefullhttps://www.spreaker.com/episode/incurable-hpv-negative-head-and-neck-cancer--59490743https://api.spreaker.com/episode/59490743Wed, 21 Aug 2024 15:00:01 +0000cancerGRACEDrs. Patel, Sheth, and Weiss discuss current treatment options and emerging data in incurable HPV negative head and neck cancer.795cancer,head,hpv,incurable,neck,negativefalsefullhttps://www.spreaker.com/episode/recurrent-metastatic-hpv-positive-head-and-neck-cancer--59490742https://api.spreaker.com/episode/59490742Wed, 14 Aug 2024 15:00:04 +0000cancerGRACEDrs. Patel, Sheth, and Weiss discuss current treatment options and emerging data in recurrent/metastatic HPV positive head and neck cancer.476cancer,head,hpv,neck,positive,recurrent/metastaticfalsefullhttps://www.spreaker.com/episode/curable-hpv-negative-head-and-neck-cancer--59490736https://api.spreaker.com/episode/59490736Wed, 07 Aug 2024 15:00:04 +0000cancerGRACEDrs. Patel, Sheth, and Weiss discuss current treatment options and emerging data in curable HPV negative head and neck cancer.338cancer,curable,head,hpv,neck,negativefalsefullhttps://www.spreaker.com/episode/curable-hpv-positive-head-and-neck-cancer--59490728https://api.spreaker.com/episode/59490728Tue, 30 Jul 2024 19:20:02 +0000cancerGRACEDrs. Patel, Sheth, and Weiss discuss current treatment options and emerging data in curable HPV positive head and neck cancer.707cancer,curable,head,hpv,neck,positivefalsefullhttps://www.spreaker.com/episode/what-is-a-bone-marrow-transplant--58336154https://api.spreaker.com/episode/58336154Wed, 12 Jun 2024 15:00:04 +0000cancerGRACEDr. Marco Ruiz explains the concept of bone marrow transplant, and how it is used in treating blood cancers.491bone,marrow,transplantfalsefullhttps://www.spreaker.com/episode/q-a-do-people-in-rural-communities-have-equal-access-to-treatment-options--58336155https://api.spreaker.com/episode/58336155Mon, 10 Jun 2024 15:00:03 +0000cancerGRACEDrs. Goodman, Phillips, Taneja, and Rajeeve discuss whether a patient's location can affect the treatments they can access and their overall prognosis.252access,communities,equal,options,rural,treatmentfalsefullhttps://www.spreaker.com/episode/q-a-is-my-clinical-trial-affecting-my-body-s-reaction-to-the-covid-19-vaccine--58336153https://api.spreaker.com/episode/58336153Wed, 05 Jun 2024 15:00:03 +0000cancerGRACEDrs. Goodman, Phillips, Taneja, and Rajeeve discuss how to navigate treatment and Covid vaccination.242blood,cancer,covid,treatment,vaccinationfalsefullhttps://www.spreaker.com/episode/bispecific-antibodies-in-myeloma-approvals-and-clinical-trials--58336152https://api.spreaker.com/episode/58336152Fri, 31 May 2024 15:00:03 +0000cancerGRACEDr. Sridevi Rajeeve discusses current FDA approved bispecific antibodies and ones coming from clinical trials.251antibodies,bispecific,clinical,myeloma,trialsfalsefullhttps://www.spreaker.com/episode/curative-strategies-for-patients-with-smoldering-multiple-myeloma--58336151https://api.spreaker.com/episode/58336151Thu, 23 May 2024 15:00:03 +0000cancerGRACEDr. Alankrita Taneja examines data from the CESAR trial, and discusses curative strategies for Smoldering Multiple Myeloma.185cesar,curative,multiple,myeloma,smoldering,strategies,trialfalsefullhttps://www.spreaker.com/episode/management-of-bispecific-antibodies-side-effects--58336150https://api.spreaker.com/episode/58336150Fri, 17 May 2024 15:00:02 +0000cancerGRACEDr. Sridevi Rajeeve discusses possible side effects from bispecific antibodies, and how to manage them.190antibodies,bispecific,effects,sidefalsefullhttps://www.spreaker.com/episode/teclistamab-talquetamab-and-elranatamab-response-rates-and-data--58336149https://api.spreaker.com/episode/58336149Fri, 10 May 2024 15:00:03 +0000cancerGRACEDr. Sridevi Rajeeve discusses the unprecedented response rates in patients treated with teclistamab, talquetamab, and elranatamab, as well as their clinical trial data.363clinical,elranatamab,talquetamab,teclistamab,trialfalsefullhttps://www.spreaker.com/episode/efficacy-of-epcoritamab-and-glofitamab-in-diffuse-large-b-cell-lymphoma--58336148https://api.spreaker.com/episode/58336148Fri, 03 May 2024 14:00:03 +0000cancerGRACEDr. Tycel Phillips examines the efficacy of two medications against diffuse large b-cell lymphoma (DLBCL)182b-cell,diffuse,dlbcl,epcoritamab,glofitamab,large,lymphomafalsefullhttps://www.spreaker.com/episode/barriers-to-biomarker-testing-cost-and-insurance--56485522https://api.spreaker.com/episode/56485522Sat, 27 Apr 2024 15:00:04 +0000cancerGRACEDr. Aakash Desai discusses how to address the issues of cost and insurance approval when obtaining biomarker testing.210biomarker,cost,insurance,testingfalsefullhttps://www.spreaker.com/episode/barriers-to-biomarker-testing-ordering-tests--56485521https://api.spreaker.com/episode/56485521Sat, 20 Apr 2024 15:00:03 +0000cancerGRACEDr. Aakash Desai emphasizes the importance of physicians ordering biomarker testing for patients with NSCLC383biomarker,nsclc,testingfalsefullhttps://www.spreaker.com/episode/the-adaura-trial-the-effect-on-egfr-treatment--56485520https://api.spreaker.com/episode/56485520Mon, 15 Apr 2024 15:00:02 +0000cancerGRACEDr. Joshua Reuss discusses the ADAURA trial, which suggested Osimertinib as treatment for EGFR+ NSCLC.386adaura,egfr+,nsclc,osimertinib,treatment,trialfalsefullhttps://www.spreaker.com/episode/biomarker-driven-therapy-for-nsclc--56485519https://api.spreaker.com/episode/56485519Sat, 13 Apr 2024 15:00:03 +0000cancerGRACEDr. Aakash Desai discusses the administration of therapy for biomarkers, and how to overcome the gaps in administration, access, and affordability.313access,administration,affordability,biomarkers,gapsfalsefullhttps://www.spreaker.com/episode/current-recommendations-and-best-practices-for-biomarker-testing--56485518https://api.spreaker.com/episode/56485518Thu, 11 Apr 2024 15:00:04 +0000cancerGRACEDr. Aakash Desai discusses the current recommendations for biomarker testing in patients with NSCLC, as well as best practices.233biomarker,nsclc,testingfalsefullhttps://www.spreaker.com/episode/the-importance-of-biomarker-testing-what-is-liquid-biopsy--56485508https://api.spreaker.com/episode/56485508Tue, 09 Apr 2024 15:00:03 +0000cancerGRACEDr. Aakash Desai details the importance of biomarker testing, and discusses the method of liquid biopsy to do so.295biomarker,biopsy,cancer,liquid,lungfalsefullhttps://www.spreaker.com/episode/biomarkers-in-nsclc--56485494https://api.spreaker.com/episode/56485494Tue, 09 Apr 2024 02:00:01 +0000cancerGRACEDr. Aakash Desai gives a basic overview of biomarkers, and discusses which ones are important for patients with NSCLC.355biomarkers,cancer,lung,nsclcfalsefullhttps://www.spreaker.com/episode/key-points-from-the-adaura-trial-osimertinib--56485523https://api.spreaker.com/episode/56485523Thu, 30 Nov 2023 16:00:03 +0000cancerGRACEDr. Joshua Reuss examines important details learned during the ADAURA trial, including overall survival, reduced risk of brain mets, and side effects.374adaura,brain,effect,mets,overall,side,survival,trialfalsefullhttps://www.spreaker.com/episode/biomarkers-in-nsclc--57253287https://api.spreaker.com/episode/57253287Thu, 23 Nov 2023 16:00:03 +0000cancerGRACEDr. Aakash Desai gives a basic overview of biomarkers, and discusses which ones are important for patients with NSCLC.355biomarkers,cancer,lung,nsclc,patientsfalsefullhttps://www.spreaker.com/episode/the-importance-of-biomarker-testing-what-is-liquid-biopsy--57253297https://api.spreaker.com/episode/57253297Thu, 16 Nov 2023 16:00:03 +0000cancerGRACEDr. Aakash Desai details the importance of biomarker testing, and discusses the method of liquid biopsy to do so.295biomarker,biopsy,liquid,testingfalsefullhttps://www.spreaker.com/episode/barriers-to-biomarker-testing-cost-and-insurance--57253310https://api.spreaker.com/episode/57253310Fri, 10 Nov 2023 01:00:02 +0000cancerGRACEDr. Aakash Desai discusses how to address the issues of cost and insurance approval when obtaining biomarker testing.210approval,biomarker,cost,insurance,testingfalsefullhttps://www.spreaker.com/episode/neoadjuvant-treatment-for-patients-with-nsclc--56485525https://api.spreaker.com/episode/56485525Fri, 27 Oct 2023 12:00:03 +0000cancerGRACEDr. Joshua Reuss examines data on neoadjuvant targeted therapy.191neoadjuvant,nsclc,patients,treatmentfalsefullhttps://www.spreaker.com/episode/the-alina-trial-for-alk-nsclc--56485524https://api.spreaker.com/episode/56485524Sat, 21 Oct 2023 12:00:02 +0000cancerGRACEDr. Joshua Reuss gives a brief description of the ongoing Alina trial for patients with ALK+ NSCLC.73alina,alk+,nsclc,trialfalsefullhttps://www.spreaker.com/episode/local-therapy-for-limited-metastatic-nsclc--56485528https://api.spreaker.com/episode/56485528Tue, 17 Oct 2023 12:00:03 +0000cancerGRACEDr. Puneeth Iyengar discusses the concept of using local therapy as an additional treatment for limited metastatic NSCLC, including Stereotactic Body Radiation Therapy (SBRT).257limited,local,metastatic,nsclc,therapyfalsefullhttps://www.spreaker.com/episode/immunotherapy-for-patients-with-resectable-nsclc-and-a-driver-mutation--56485529https://api.spreaker.com/episode/56485529Tue, 10 Oct 2023 12:00:03 +0000cancerGRACEDr. Joshua Reuss explains why immunotherapy is not typically given to patients with resectable NSCLC and a driver mutation.125driver,immunotherapy,mutation,nsclc,patients,resectablefalsefullhttps://www.spreaker.com/episode/treatment-options-for-patients-with-locally-advanced-unresectable-nsclc--56485530https://api.spreaker.com/episode/56485530Tue, 03 Oct 2023 12:00:02 +0000cancerGRACEDr. Joshua Reuss discusses treatment options for patients with locally advanced NSCLC, and how to proceed while waiting for trial data.119advanced,locally,nsclc,options,patients,treatment,unresectablefalsefullhttps://www.spreaker.com/episode/local-therapy-for-nsclc-patients-after-frontline-therapy--56485531https://api.spreaker.com/episode/56485531Wed, 27 Sep 2023 12:00:03 +0000cancerGRACEDr. Puneeth Iyengar discusses local therapy options for patients with metastatic disease who have received a front line therapy.472frontline,local,nsclc,patients,therapyfalsefullhttps://www.spreaker.com/episode/the-role-of-the-patient-as-advocate--56485526https://api.spreaker.com/episode/56485526Sun, 24 Sep 2023 07:00:02 +0000cancerGRACEDr. Joshua Reuss discusses what the patient can do to advocate for themselves during treatment.179advocate,patient,rolefalsefullhttps://www.spreaker.com/episode/targeted-therapy-before-surgery-in-patients-with-resectable-nsclc-and-driver-mutation--56485532https://api.spreaker.com/episode/56485532Wed, 20 Sep 2023 12:00:02 +0000cancerGRACEDr. Joshua Reuss discusses considerations and questions for targeted therapy before surgery.192driver,mutation,nsclc,patients,resectable,surgery,targeted,therapyfalsefullhttps://www.spreaker.com/episode/local-therapy-for-patients-with-oligoprogressive-nsclc--56485533https://api.spreaker.com/episode/56485533Fri, 15 Sep 2023 12:00:02 +0000cancerGRACEDr. Puneeth Iyengar discusses local therapy treatment options for patients who have oligoprogressive disease.327cancer,local,lung,nsclc,oligoprogressive,options,patients,therapy,treatmentfalsefullhttps://www.spreaker.com/episode/the-future-of-local-therapy-in-lung-cancer--56485534https://api.spreaker.com/episode/56485534Thu, 14 Sep 2023 23:20:01 +0000cancerGRACEDr. Puneeth Iyengar examines what has been learned from studies, what still remains unanswered, and future directions of local therapy treatments for patients with NSCLC.175cancer,local,lung,nsclc,patients,radiology,therapy,treatmentsfalsefullhttps://www.spreaker.com/episode/adding-to-targeted-therapy-current-statistics-and-biology--56485527https://api.spreaker.com/episode/56485527Thu, 14 Sep 2023 22:36:12 +0000cancerGRACEDr. Puneeth Iyengar looks at current statistics for methods of adding to targeted therapy, as well as giving an overview of biology in treatment.317biology,current,statistics,targetedfalsefullhttps://www.spreaker.com/episode/the-importance-of-prostate-cancer-screening--51397543https://api.spreaker.com/episode/51397543Fri, 01 Sep 2023 15:00:02 +0000cancerGRACEDr. Rana McKay discusses why it's crucial to get a prostate cancer screening.225cancer,cancergrace,prostate,screeningfalsefullhttps://www.spreaker.com/episode/saman-ya-paramarsa-mudde-common-consultation-issues--53987789
(Dr. Alankrita Taneja discusses common consultation issues seen in transgender patients, and the importance of proper monitoring.)]]>https://api.spreaker.com/episode/53987789Wed, 30 Aug 2023 08:00:02 +0000cancerGRACEडॉ. अलंकृता तनेजा ट्रांसजेंडर मरीजों में देखे जाने वाले सामान्य परामर्श मुद्दों पर चर्चा करती हैं, और सही मॉनिटरिंग का महत्व बताती हैं। (Dr. Alankrita Taneja discusses common consultation issues seen in transgender patients, and the importance of...
(Dr. Alankrita Taneja discusses common consultation issues seen in transgender patients, and the importance of proper monitoring.)]]>232cancer,consultation,hindi,india,transgenderfalsefullhttps://www.spreaker.com/episode/purusatvikarana-cikitsa-aura-dvitiya-erithrosa-itosisa-masculinizing-therapy-and-secondary-erythrocytosis--53987788
(Dr. Alankrita Taneja discusses testosterone therapy and the risks that come with it, including secondary erythrocytosis.)]]>https://api.spreaker.com/episode/53987788Wed, 23 Aug 2023 08:00:03 +0000cancerGRACEडॉ. अलंकृता तनेजा टेस्टोस्टेरोन थेरेपी और इसके साथ आने वाले जोखिमों पर चर्चा करती हैं, जिसमें द्वितीय एरिथ्रोसाइटोसिस भी शामिल है। (Dr. Alankrita Taneja discusses testosterone therapy and the risks that come with it, including secondary erythrocytosis.)
(Dr. Alankrita Taneja discusses testosterone therapy and the risks that come with it, including secondary erythrocytosis.)]]>481cancer,erythrocytosis,hindi,india,masculinizing,secondary,testosterone,therapyfalsefullhttps://www.spreaker.com/episode/sikala-sela-roga-aura-jendara-apharminga-harmona-therepi-sickle-cell-disease-and-gender-affirming-hormone-therapy--53987787
(Dr. Alankrita Taneja examines the treatment options for people with Sickle Cell Disease who are undergoing gender affirming hormone therapy.)]]>https://api.spreaker.com/episode/53987787Wed, 16 Aug 2023 08:30:02 +0000cancerGRACEडॉ. अलंकृता तनेजा सिकल सेल रोग वाले लोगों के लिए उपचार विकल्पों की जांच करती हैं, जो जेंडर अफर्मिंग हार्मोन थेरेपी के अधीन हैं। (Dr. Alankrita Taneja examines the treatment options for people with Sickle Cell Disease who are undergoing gender...
(Dr. Alankrita Taneja examines the treatment options for people with Sickle Cell Disease who are undergoing gender affirming hormone therapy.)]]>189affirming,cell,disease,gender,hormone,sickle,therapyfalsefullhttps://www.spreaker.com/episode/phemina-ijinga-therepi-aura-thrombosisa-feminizing-therapy-and-thrombosis--53987786
(Dr. Alankrita Taneja examines estrogen therapy and its potential side effects.)]]>https://api.spreaker.com/episode/53987786Wed, 09 Aug 2023 08:30:02 +0000cancerGRACEडॉ. अलंकृता तनेजा एस्ट्रोजन थेरेपी और इसके संभावित दुष्प्रभावों की जांच करती हैं। (Dr. Alankrita Taneja examines estrogen therapy and its potential side effects.)
(Dr. Alankrita Taneja examines estrogen therapy and its potential side effects.)]]>577cancer,effects,estrogen,hindi,india,side,therapy,thrombosisfalsefullhttps://www.spreaker.com/episode/bharata-mem-transajendara-mudde-transgender-issues-in-india--53987785(Dr. Alankrita Taneja gives a brief description of terminology and social issues surrounding transgender people in India.)]]>https://api.spreaker.com/episode/53987785Fri, 04 Aug 2023 08:30:03 +0000cancerGRACEडॉ. अलंकृता तनेजा भारत में ट्रांसजेंडर लोगों के संबंधित शब्दावली और सामाजिक मुद्दों का एक संक्षिप्त विवरण देती है। (Dr. Alankrita Taneja gives a brief description of terminology and social issues surrounding transgender people in India.)(Dr. Alankrita Taneja gives a brief description of terminology and social issues surrounding transgender people in India.)]]>185cancer,hindi,india,issues,social,transgenderfalsefullhttps://www.spreaker.com/episode/neoadjuvant-therapy-in-melanoma-does-it-give-a-better-immune-response--51363354https://api.spreaker.com/episode/51363354Wed, 07 Jun 2023 22:10:02 +0000cancerGRACEDr. Vernon Sondak makes the argument that neoadjuvant therapy leads to a better immune response in patients with melanoma.336immune,melanoma,neoadjuvant,therapyfalsefullhttps://www.spreaker.com/episode/neoadjuvant-therapy-for-melanoma--51363355https://api.spreaker.com/episode/51363355Fri, 02 Jun 2023 22:10:01 +0000cancerGRACEDr. Vernon Sondak discusses the pros and cons of neoadjuvant therapy, or receiving treatment before surgery.446melanoma,neoadjuvant,therapyfalsefullhttps://www.spreaker.com/episode/adjuvant-therapy-for-melanoma--51363356https://api.spreaker.com/episode/51363356Mon, 29 May 2023 22:05:01 +0000cancerGRACEDr. Vernon Sondak discusses the pros and cons of adjuvant therapy, or receiving treatment after surgery.194adjuvant,melanoma,therapyfalsefullhttps://www.spreaker.com/episode/adjuvant-therapy-in-stage-3-and-4-melanoma--51363357https://api.spreaker.com/episode/51363357Fri, 26 May 2023 22:05:01 +0000cancerGRACEDr. Meredith McKean discusses recent findings in adjuvant therapy for patients with stage 3 or 4 melanoma.3423,4,adjuvant,melanoma,stage,therapyfalsefullhttps://www.spreaker.com/episode/patient-selection-for-first-line-therapy-in-stage-4-melanoma--51363358https://api.spreaker.com/episode/51363358Mon, 22 May 2023 22:05:01 +0000cancerGRACEDr. Vernon Sondak discusses current patient treatment standards, including using immune therapy before targeted therapy in unresectable stage 4 disease.3604,first,line,melanoma,stage,therapyfalsefullhttps://www.spreaker.com/episode/neoadjuvant-therapy-in-melanoma-the-prado-trial--51363353https://api.spreaker.com/episode/51363353Fri, 19 May 2023 18:35:01 +0000cancerGRACEDr. Vernon Sondak examines the PRADO trial and what it means for drug regimens moving forward.228melanoma,prado,trialfalsefullhttps://www.spreaker.com/episode/major-advances-in-uveal-melanoma--51363351https://api.spreaker.com/episode/51363351Mon, 15 May 2023 18:35:01 +0000cancerGRACEDr. Michael Postow reviews major advances in uveal melanoma.213melanoma,uvealfalsefullhttps://www.spreaker.com/episode/clinical-trials-in-melanoma--51363350https://api.spreaker.com/episode/51363350Sun, 14 May 2023 18:35:01 +0000cancerGRACEDr. Michael Postow discusses the importance of clinical trials in melanoma.278clinical,melanoma,trialsfalsefullhttps://www.spreaker.com/episode/incidence-trends-in-melanoma--51363349https://api.spreaker.com/episode/51363349Sat, 13 May 2023 18:35:01 +0000cancerGRACEDr. Vernon Sondak examines the troubling expected increase in melanoma cases.264melanoma,trendsfalsefullhttps://www.spreaker.com/episode/side-effects-of-immunotherapy-in-melanoma--51363347https://api.spreaker.com/episode/51363347Thu, 11 May 2023 18:30:01 +0000cancerGRACEDr. Michael Postow looks at potential side effects for patients with melanoma who receive immunotherapy.234effects,immunotherapy,melanoma,sidefalsefullhttps://www.spreaker.com/episode/treatment-for-metastatic-melanoma--51363352https://api.spreaker.com/episode/51363352Mon, 01 May 2023 15:00:02 +0000cancerGRACEDr. Vernon Sondak looks at the recent improvements in treatment of metastatic melanoma, including the Relativity 047 trial.365cancer,cancergrace,melanoma,metastatic,relativity,treatment,trialfalsefullhttps://www.spreaker.com/episode/braf-mutated-melanoma--51363346https://api.spreaker.com/episode/51363346Mon, 06 Mar 2023 16:00:01 +0000cancerGRACEDr. Michael Postow discusses BRAF mutation in melanoma.316braf,in,melanoma,mutationfalsefullhttps://www.spreaker.com/episode/melanoma-and-current-treatment-options--51363338https://api.spreaker.com/episode/51363338Tue, 28 Feb 2023 16:00:01 +0000cancerGRACEDr. Michael Postow gives a brief explanation of what melanoma is and how it forms, and discusses current treatment options.394melanomafalsefullhttps://www.spreaker.com/episode/emerging-types-of-car-t-cell-therapy--51028765https://api.spreaker.com/episode/51028765Wed, 22 Feb 2023 16:00:02 +0000cancerGRACEDr. Aaron Goodman gives a brief explanation of three current types of CAR-T cell therapy.266car-t,cell,therapyfalsefullhttps://www.spreaker.com/episode/car-t-cell-therapy-side-effects--51028736https://api.spreaker.com/episode/51028736Wed, 15 Feb 2023 16:00:02 +0000cancerGRACEDr. Aaron Goodman discusses two main side effects of CAR-T Cell Therapy: Cytokine Release Syndrome and ICANS.278car-t,cell,cytokine,effects,icans,release,side,syndromefalsefullhttps://www.spreaker.com/episode/car-t-cell-therapy-for-patients-with-relapsed-diffuse-large-b-cell-lymphoma--51028715https://api.spreaker.com/episode/51028715Thu, 09 Feb 2023 01:40:01 +0000cancerGRACEDr. Aaron Goodman explains the process of CAR-T Cell Therapy in Blood Cancers304falsefullhttps://www.spreaker.com/episode/treatment-options-for-relapsed-diffuse-large-b-cell-lymphoma--51028709https://api.spreaker.com/episode/51028709Wed, 08 Feb 2023 00:39:02 +0000cancerGRACEDr. Aaron Goodman discusses treatment options for patients who relapse after R-CHOP first line treatment.236first,line,r-chop,relapse,treatmentfalsefullhttps://www.spreaker.com/episode/emerging-immunotherapy-treatments-for-b-cell-non-hodgkin-s-lymphoma-bispecific-antibodies--51028627https://api.spreaker.com/episode/51028627Wed, 08 Feb 2023 00:37:34 +0000cancerGRACEDr. Joshua Brody discusses the use of bispecific antibodies in the treatment of Non-Hodgkin's Lymphoma.313antibodies,bispecific,lymphoma,non-hodgkin's,treatmentfalsefullhttps://www.spreaker.com/episode/emerging-immunotherapy-treatments-for-b-cell-non-hodgkin-s-lymphoma-car-t-cells--51028588https://api.spreaker.com/episode/51028588Wed, 08 Feb 2023 00:36:18 +0000cancerGRACEDr. Joshua Brody gives an in-depth explanation of CAR-T cells and their role in treating Non-Hodgkin's Lymphoma.576car-t,lymphoma,nonhodgkins,treatmentfalsefullhttps://www.spreaker.com/episode/covid-19-and-lung-cancer-screening--51397530https://api.spreaker.com/episode/51397530Wed, 08 Feb 2023 00:34:27 +0000cancerGRACEDr. Devika Das gives a brief overview of the importance of lung cancer screening during a pandemic.179cancer,lung,screeningfalsefullhttps://www.spreaker.com/episode/who-should-receive-lung-cancer-screening--51397532https://api.spreaker.com/episode/51397532Thu, 05 Jan 2023 16:00:03 +0000cancerGRACEDr. Devika Das discusses which patients should receive lung cancer screening.393cancer,importance,lung,screening,should,whofalsefullhttps://www.spreaker.com/episode/what-is-involved-in-lung-cancer-screening--51397533https://api.spreaker.com/episode/51397533Wed, 28 Dec 2022 16:00:02 +0000cancerGRACEDr. Devika Das explains the process of getting a lung cancer screening.187cancer,lung,process,screeningfalsefullhttps://www.spreaker.com/episode/timelines-in-cancer-care--51397537https://api.spreaker.com/episode/51397537Wed, 21 Dec 2022 16:00:02 +0000cancerGRACEDr. Devika Das examines the first domain of quality cancer care: finding the cancer early.334cancer,care,timeline,treatmentfalsefullhttps://www.spreaker.com/episode/efficiency-and-effectiveness-of-cancer-care--51397538https://api.spreaker.com/episode/51397538Wed, 14 Dec 2022 16:00:02 +0000cancerGRACEDr. Devika Das discusses the importance of staging of cancer, and of testing for mutations.306cancer,lung,mutation,stagingfalsefullhttps://www.spreaker.com/episode/is-my-lung-cancer-mutation-genetic--51397539https://api.spreaker.com/episode/51397539Wed, 07 Dec 2022 16:00:03 +0000cancerGRACEDr. Devika Das discusses the genetic component of lung cancer mutations, and if they can be passed on.174cancer,genetic,lung,mutationfalsefullhttps://www.spreaker.com/episode/the-prevalence-of-breast-cancer-and-tools-for-early-detection--51397545https://api.spreaker.com/episode/51397545Wed, 30 Nov 2022 21:05:01 +0000cancerGRACEDr. Medhavi Gupta discusses how common breast cancer is, and why it is crucial to get screened.246breast,cancer,cancergrace,common,screeningfalsefullhttps://www.spreaker.com/episode/types-of-imaging-tests-for-breast-cancer--51397547https://api.spreaker.com/episode/51397547Wed, 23 Nov 2022 16:00:02 +0000cancerGRACEDr. Medhavi Gupta discusses mammograms, ultrasounds, and MRIs for breast cancer screening.202breast,cancer,cancergrace,mammogram,mri,screening,ultrasoundfalsefullhttps://www.spreaker.com/episode/anomalies-on-breast-cancer-imaging-next-steps--51397551https://api.spreaker.com/episode/51397551Wed, 16 Nov 2022 16:00:02 +0000cancerGRACEDr. Medhavi Gupta examines the steps a patient could go through after an abnormality is found on a breast cancer screening.149abnormality,breast,cancer,cancergrace,screeningfalsefullhttps://www.spreaker.com/episode/the-importance-of-patient-centered-care--51397542https://api.spreaker.com/episode/51397542Thu, 10 Nov 2022 16:00:02 +0000cancerGRACEDr. Devika Das examines the importance of patient centered care, including safety throughout the process, and equitable care for all.314cancer,cancergrace,care,centered,equitable,patient,treatmentfalsefullhttps://www.spreaker.com/episode/symptoms-of-breast-cancer--51397553https://api.spreaker.com/episode/51397553Wed, 09 Nov 2022 16:00:03 +0000cancerGRACEDr. Medhavi Gupta discusses symptoms that may be seen in patients with breast cancer.133breast,cancer,cancergrace,symptomsfalsefullhttps://www.spreaker.com/episode/key-players-for-lung-cancer-program-success--51397534https://api.spreaker.com/episode/51397534Tue, 08 Nov 2022 16:00:02 +0000cancerGRACEDr. Devika Das discusses comprehensive care in lung cancer, and who is involved from screening to treatment.190cancer,cancergrace,care,lung,screening,treatmentfalsefullhttps://www.spreaker.com/episode/treatment-after-diagnosis-of-breast-cancer--51397555https://api.spreaker.com/episode/51397555Wed, 02 Nov 2022 15:00:01 +0000cancerGRACEDr. Medhavi Gupta examines how treatment can look for patients diagnosed with breast cancer.226breast,cancer,cancergrace,treatmentfalsefullhttps://www.spreaker.com/episode/goals-of-lung-cancer-advocacy--51397535https://api.spreaker.com/episode/51397535Tue, 01 Nov 2022 15:00:01 +0000cancerGRACEDr. Devika Das talks about goals for lung cancer advocacy, including broader testing.161advocacy,cancer,cancergrace,goals,lung,testingfalsefullhttps://www.spreaker.com/episode/the-importance-of-breast-cancer-screening--51397557https://api.spreaker.com/episode/51397557Thu, 27 Oct 2022 18:54:30 +0000cancerGRACEDr. Medhavi Gupta reiterates the importance of breast cancer screening in detection and treatment.96breast,cancer,cancergrace,screening,treatmentfalsefullhttps://www.spreaker.com/episode/prevalence-of-egfr-mutant-nsclc-in-asian-and-caucasian-communities--50793517https://api.spreaker.com/episode/50793517Thu, 20 Oct 2022 03:15:01 +0000cancerGRACEDr. Chul Kim explains EGFR mutations and their prevalence, particularly in Asian and Caucasian communities.193asian,caucasian,communities,egfr,mutation,nsclc,prevalencefalsefullhttps://www.spreaker.com/episode/advancements-of-targeted-therapy-for-egfr-mutations-in-nsclc--50793523https://api.spreaker.com/episode/50793523Wed, 12 Oct 2022 15:00:02 +0000cancerGRACEDr. Chul Kim gives a brief history of targeted therapies, and discusses EGFR-TKIs.194chul,discusses,dr.,egfr,history,kim,nsclc,targeted,therapies,tkifalsefullhttps://www.spreaker.com/episode/choosing-first-line-therapy-in-egfr-mutations--50793528https://api.spreaker.com/episode/50793528Tue, 04 Oct 2022 15:00:01 +0000cancerGRACEDr. Chul Kim discusses how first-line therapies are chosen.120egfr,first,line,mutations,nsclc,therapyfalsefullhttps://www.spreaker.com/episode/osimertinib-and-the-flaura-trial--50793529https://api.spreaker.com/episode/50793529Thu, 29 Sep 2022 03:10:02 +0000cancerGRACEDr. Chul Kim takes a look at the FLAURA Trial on untreated advanced NSCLC, and the role Osimertinib played in the trial.342advanced,chul,dr.,flaura,kim,nsclc,osimertinib,trial,untreatedfalsefullhttps://www.spreaker.com/episode/preferential-timing-for-molecular-testing-in-nsclc--50793551https://api.spreaker.com/episode/50793551Wed, 21 Sep 2022 15:10:01 +0000cancerGRACEDr. Tejas Patil discusses when to utilize molecular testing in patients with NSCLC. For full video visit cancerGRACE.org.236molecular,nsclc,preferential,testing,timingfalsefullhttps://www.spreaker.com/episode/immunotherapy-before-surgery-in-nsclc--50793531https://api.spreaker.com/episode/50793531Wed, 14 Sep 2022 15:10:02 +0000cancerGRACEDr. Jack West examines the concept of immunotherapy before surgery.500before,immunotherapy,nsclc,surgeryfalsefullhttps://www.spreaker.com/episode/immunotherapy-for-patients-with-driver-mutation--50793532https://api.spreaker.com/episode/50793532Wed, 07 Sep 2022 15:00:02 +0000cancerGRACEDr. Jack West discusses how immunotherapy is used for patients with driver mutations.379cancer,dr.,driver,immunotherapy,jack,lung,mutations,nsclc,treatment,westfalsefullhttps://www.spreaker.com/episode/immunotherapy-for-oligometastatic-disease--50793533https://api.spreaker.com/episode/50793533Thu, 01 Sep 2022 03:05:01 +0000cancerGRACEDr. Jack West discusses immunotherapy in patients who have oligometastatic disease.294cancer,dr.,immunotherapy,jack,lung,nsclc,oligometastatic,patients,stage4,treatment,westfalsefullhttps://www.spreaker.com/episode/gene-mutations-in-nsclc--50793538https://api.spreaker.com/episode/50793538Tue, 30 Aug 2022 03:00:02 +0000cancerGRACEDr. Tejas Patil discusses gene mutations in NSCLC382dr.,gene,mutations,nsclc,patil,tejasfalsefullhttps://www.spreaker.com/episode/testing-methodology-for-nsclc-immunohistochemistry--50793539https://api.spreaker.com/episode/50793539Sun, 28 Aug 2022 02:55:01 +0000cancerGRACEDr. Tejas Patil explains immunohistochemistry and its uses.339immunohistochemistry,methodology,nsclc,testingfalsefullhttps://www.spreaker.com/episode/testing-methodology-for-nsclc-fish--50793540https://api.spreaker.com/episode/50793540Sat, 27 Aug 2022 02:55:01 +0000cancerGRACEDr. Tejas Patil explains FISH testing for NSCLC.244dr.,fish,methodology,nsclc,patil,tejas,testingfalsefullhttps://www.spreaker.com/episode/testing-methodology-for-nsclc-pcr-testing--50793543https://api.spreaker.com/episode/50793543Fri, 26 Aug 2022 02:55:01 +0000cancerGRACEDr. Tejas Patil looks at PCR testing for NSCLC.177cancer,chain,lung,methodology,nsclc,pcr,polymerase,quantitative,reaction,testingfalsefullhttps://www.spreaker.com/episode/testing-methodology-for-nsclc-next-generation-sequencing-ngs--50793547https://api.spreaker.com/episode/50793547Thu, 25 Aug 2022 02:50:02 +0000cancerGRACEDr. Tejas Patil explains Next Generation Sequencing (NGS) in NSCLC.317generation,methodology,next,ngs,nsclc,sequencing,testingfalsefullhttps://www.spreaker.com/episode/circulating-tumor-dna-in-nsclc--50793549https://api.spreaker.com/episode/50793549Thu, 25 Aug 2022 01:47:38 +0000cancerGRACEDr. Tejas Patil gives an overview of circulating tumor DNA in patients with NSCLC.387alk,blood,cancer,circulating,dna,lung,nsclc,testing,tumor,tumorsfalsefullhttps://www.spreaker.com/episode/mesothelioma-updates-episode-6-peritoneal-disease--49646931https://api.spreaker.com/episode/49646931Wed, 06 Jul 2022 15:00:01 +0000cancerGRACEDr. Melina Marmarelis discusses the treatment of peritoneal mesothelioma.122cancer,cancergrace,mesothelioma,peritoneal,treatmentfalsefullhttps://www.spreaker.com/episode/mesothelioma-updates-episode-5-future-approaches--49646923https://api.spreaker.com/episode/49646923Tue, 28 Jun 2022 15:00:02 +0000cancerGRACEDr. Melina Marmarelis discusses ways mesothelioma may be treated in the future.238cancer,cancergrace,lung,mesothelioma,treatmentfalsefullhttps://www.spreaker.com/episode/mesothelioma-updates-episode-4-chemo-and-immunotherapy--49646916https://api.spreaker.com/episode/49646916Wed, 22 Jun 2022 01:25:01 +0000cancerGRACEDr. Melina Marmarelis discusses the use of chemotherapy with and without immunotherapy in patients with mesothelioma.425cancer,cancergrace,chemotherapy,immunotherapy,lung,mesotheliomafalsefullhttps://www.spreaker.com/episode/mesothelioma-updates-episode-3-surgical-options--49646907https://api.spreaker.com/episode/49646907Tue, 14 Jun 2022 15:00:02 +0000cancerGRACEDr. Melina Marmarelis discusses the various surgical options for patients with mesothelioma.229cancer,cancergrace,lung,mesothelioma,surgeryfalsefullhttps://www.spreaker.com/episode/mesothelioma-updates-episode-2-diagnosis-and-staging--49646897https://api.spreaker.com/episode/49646897Tue, 07 Jun 2022 15:00:02 +0000cancerGRACEDr. Melina Marmarelis discusses how doctors diagnose mesothelioma and determine the stage of the disease.188cancer,cancergrace,lung,mesothelioma,stagefalsefullhttps://www.spreaker.com/episode/mesothelioma-updates-episode-1-epidemiology--49646875https://api.spreaker.com/episode/49646875Wed, 01 Jun 2022 15:00:02 +0000cancerGRACEDr. Melina Marmarelis discusses the epidemiology of mesothelioma.248cancer,cancergrace,epidemiology,lung,mesotheliomafalsefullhttps://www.spreaker.com/episode/targeted-therapy-forum-episode-10-cost-and-treatment-options--49276482https://api.spreaker.com/episode/49276482Wed, 25 May 2022 15:00:02 +0000cancerGRACEDoctors Jared Weiss, Ibiayi Dagogo-Jack, and Jeffrey Thompson discuss their opinions on costs and treatment options, such as double dose Osimertinib170cancer,lung,options,osimertinib,treatmentfalsefullhttps://www.spreaker.com/episode/targeted-therapies-forum-episode-9-telemedicine-and-cancer--49276471https://api.spreaker.com/episode/49276471Wed, 18 May 2022 15:00:02 +0000cancerGRACEDoctors Jared Weiss, Ibiayi Dagogo-Jack, and Jeffrey Thompson discuss the role telemedicine can play in cancer treatment.261cancer,cancergrace,telemedicine,treatmentfalsefullhttps://www.spreaker.com/episode/targeted-therapies-forum-episode-8-detecting-tki-resistance-with-liquid-biopsy--49158144https://api.spreaker.com/episode/49158144Wed, 20 Apr 2022 15:00:02 +0000cancerGRACEDoctors Jared Weiss, Ibiayi Dagogo-Jack, and Jeffrey Thompson discuss the effectiveness of liquid biopsies at detecting TKI resistance for fusions such as ALK, ROS1, and RET.231alk,biopsy,cancer,cancergrace,liquid,lung,ret,ros1,targeted,therapy,tkifalsefullhttps://www.spreaker.com/episode/targeted-therapies-forum-episode-7-pleural-fluid-or-blood-biopsy--49158133https://api.spreaker.com/episode/49158133Wed, 13 Apr 2022 15:00:03 +0000cancerGRACEDoctors Jared Weiss, Ibiayi Dagogo-Jack, and Jeffrey Thompson discuss whether there is a case for testing both pleural fluid and blood biopsy.237biopsy,blood,cancer,fluid,lung,pleural,targeted,therapy,treatmentfalsefullhttps://www.spreaker.com/episode/targeted-therapies-forum-episode-6-coverage-cost-and-standard-of-care-for-biopsy--49158120https://api.spreaker.com/episode/49158120Wed, 06 Apr 2022 15:00:03 +0000cancerGRACEDoctors Jared Weiss, Ibiayi Dagogo-Jack, and Jeffrey Thompson discuss the coverage, cost, and standard of care for liquid and tissue biopsy monitoring.297biopsy,cancer,cancergrace,cost,coverage,lung,targeted,therapyfalsefullhttps://www.spreaker.com/episode/targeted-therapies-forum-episode-5-circulating-tumor-dna--49158104https://api.spreaker.com/episode/49158104Fri, 01 Apr 2022 15:00:02 +0000cancerGRACEDoctors Jared Weiss, Ibiayi Dagogo-Jack, and Jeffrey Thompson discuss whether circulating tumor DNA testing will replace marker testing.209cancer,cancergrace,circulating,dna,lung,targeted,therapy,treatment,tumorfalsefullhttps://www.spreaker.com/episode/targeted-therapies-forum-episode-4-diagnosis-and-testing-relevance--49158081https://api.spreaker.com/episode/49158081Mon, 28 Mar 2022 19:36:25 +0000cancerGRACEDoctors Jared Weiss, Ibiayi Dagogo-Jack, and Jeffrey Thompson discuss which tests are relevant for which diagnoses in lung cancer.410cancer,diagnosis,lung,testsfalsefullhttps://www.spreaker.com/episode/targeted-therapies-forum-episode-2-the-complimentary-use-of-liquid-and-tissue-biopsies--48998680https://api.spreaker.com/episode/48998680Sat, 19 Mar 2022 15:00:02 +0000cancerGRACEDoctors Jared Weiss, Ibiayi Dagogo-Jack, and Jeffrey Thompson discuss the usage of liquid and tissue biopsies in patients with acquired resistance.330acquired,biopsy,cancer,liquid,lung,resistance,targeted,therapy,tissuefalsefullhttps://www.spreaker.com/episode/targeted-therapies-episode-3-anxiety-and-symptom-burden--48998707https://api.spreaker.com/episode/48998707Tue, 15 Mar 2022 02:00:02 +0000cancerGRACEDoctors Jared Weiss, Ibiayi Dagogo-Jack, and Jeffrey Thompson discuss anxiety and symptom burden, and balancing the wait for biopsy results vs. starting treatment.300anxiety,biopsy,burden,cancer,lung,symptom,treatmentfalsefullhttps://www.spreaker.com/episode/targeted-therapies-forum-2021-episode-1-liquid-and-tissue-biopsies-in-acquired-resistance--48929115https://api.spreaker.com/episode/48929115Fri, 04 Mar 2022 01:00:02 +0000cancerGRACEDoctors Jared Weiss, Ibiayi Dagogo-Jack, and Jeffrey Thompson discuss the challenges and uses of liquid and tissue biopsies in patients with acquired resistance.544acquired,biopsies,cancer,liquid,lung,resistance,tissuefalsefullhttps://www.spreaker.com/episode/melanoma-updates-molecular-profiling-and-driver-mutations-in-melanoma-treatment--48428423Dr. Meredith McKean discusses molecular profiling and driver mutations in patients with melanoma.
A huge thank you to our sponsors #Merck and #Exelixis!

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/48428423Fri, 04 Feb 2022 16:00:00 +0000cancerGRACEMeredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for...Dr. Meredith McKean discusses molecular profiling and driver mutations in patients with melanoma.
A huge thank you to our sponsors #Merck and #Exelixis!

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>516cancer,cancergrace,driver,melanoma,molecular,mutations,patients,profilingfalsefullhttps://www.spreaker.com/episode/melanoma-updates-the-importance-of-screening-for-skin-cancers--48428406
Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma.
Dr. Meredith McKean discusses molecular profiling and driver mutations in patients with melanoma.
A huge thank you to our sponsors #Merck and #Exelixis!

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/48428406Tue, 01 Feb 2022 19:22:00 +0000cancerGRACEDr. Meredith McKean discusses the importance of skin cancer screenings. Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist...
Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma.
Dr. Meredith McKean discusses molecular profiling and driver mutations in patients with melanoma.
A huge thank you to our sponsors #Merck and #Exelixis!

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>235cancer,cancergrace,melanoma,screening,skinfalsefullhttps://www.spreaker.com/episode/melanoma-updates-leptomeningeal-disease-brain-mets-in-melanoma--48428459
Dr. Roman Groisberg discusses Leptomeningeal disease and brain metastases in melanoma patients.

A huge thank you to our sponsors #Merck and #Exelixis!

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/48428459Tue, 01 Feb 2022 16:00:00 +0000cancerGRACEMeredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for...
Dr. Roman Groisberg discusses Leptomeningeal disease and brain metastases in melanoma patients.

A huge thank you to our sponsors #Merck and #Exelixis!

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>353brain,cancer,cancergrace,leptomeningeal,melanoma,metastasesfalsefullhttps://www.spreaker.com/episode/melanoma-updates-the-role-of-neoadjuvant-treatment-in-melanoma-care--48428384
Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma.
Dr. Meredith McKean discusses molecular profiling and driver mutations in patients with melanoma.
A huge thank you to our sponsors #Merck and #Exelixis!

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/48428384Mon, 24 Jan 2022 19:21:15 +0000cancerGRACEDr. Meredith McKean discusses neoadjuvant treatment for melanoma patients. Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist...
Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma.
Dr. Meredith McKean discusses molecular profiling and driver mutations in patients with melanoma.
A huge thank you to our sponsors #Merck and #Exelixis!

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>365cancer,cancergrace,melanoma,neoadjuvant,treatmentfalsefullhttps://www.spreaker.com/episode/melanoma-updates-treatment-options-for-metastatic-melanoma--48428368
Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma.

A huge thank you to our sponsors #Merck and #Exelixis!

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/48428368Mon, 24 Jan 2022 19:20:17 +0000cancerGRACEDr. Douglas Johnson discusses treatment options for patients with metastatic melanoma. Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical...
Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma.

A huge thank you to our sponsors #Merck and #Exelixis!

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>449cancer,cancergrace,melanoma,metastatic,treatmentfalsefullhttps://www.spreaker.com/episode/melanoma-updates-potential-toxicities-associated-with-immunotherapy-in-the-treatment-of-melanoma--48428325
Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma.

A huge thank you to our sponsors #Merck and #Exelixis!

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/48428325Mon, 24 Jan 2022 19:19:16 +0000cancerGRACEDr. Douglas Johnson discusses the potential toxicities that are associated with immunotherapy in melanoma patients. Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt,...
Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma.

A huge thank you to our sponsors #Merck and #Exelixis!

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>396cancer,cancergrace,immunotherapy,melanoma,toxicitiesfalsefullhttps://www.spreaker.com/episode/brain-metastases-in-breast-cancer-treatment-options-and-efficacy--46706339https://api.spreaker.com/episode/46706339Mon, 24 Jan 2022 16:00:03 +0000cancerGRACEBrain Metastases in Breast Cancer, Treatment Options and Efficacy with Dr. Medhavi Gupta and Dr. Nancy Lin526brain,breast,cancer treatment,metastasesfalsefullhttps://www.spreaker.com/episode/brain-metastases-in-breast-cancer-risks-of-developing-brain-metastasis-in-breast-cancer--46706338https://api.spreaker.com/episode/46706338Mon, 24 Jan 2022 16:00:03 +0000cancerGRACEBrain Metastases in Breast Cancer, Risks of Developing Brain Metastasis in Breast Cancer with Dr. Medhavi Gupta and Dr. Jessica Young411brain,breast,cancer,metastases,metastasisfalsefullhttps://www.spreaker.com/episode/telemedicine-vs-in-person-treatment-what-have-we-learned--48425734https://api.spreaker.com/episode/48425734Mon, 24 Jan 2022 15:41:02 +0000cancerGRACEDr. Jack West, Dr. Benjamin Levy, and Dr. Jared Weiss discuss the recent trends and lessons learned from Covid-19 in telemedicine for cancer patients.353cancer,covid,telemedicinefalsefullhttps://www.spreaker.com/episode/is-there-a-place-for-telemedicine-in-oncology--48425724https://api.spreaker.com/episode/48425724Mon, 24 Jan 2022 15:39:33 +0000cancerGRACEDr. Jack West, Dr. Benjamin Levy, and Dr. Jared Weiss discuss the benefits and drawbacks of telemedicine for cancer patients.863cancer,telemedicinefalsefullhttps://www.spreaker.com/episode/opening-up-and-masking-is-it-safe--48425704https://api.spreaker.com/episode/48425704Mon, 24 Jan 2022 15:38:23 +0000cancerGRACEDr. Jack West, Dr. Benjamin Levy, and Dr. Jared Weiss discuss the safety of masking in opened businesses during the pandemic, especially for cancer patients.506cancer,covid,mask,pandemicfalsefullhttps://www.spreaker.com/episode/the-oncologist-s-role-educating-patients-during-a-pandemic--48425684https://api.spreaker.com/episode/48425684Mon, 24 Jan 2022 15:36:46 +0000cancerGRACEDr. Jack West, Dr. Benjamin Levy, and Dr. Jared Weiss discuss the role of oncologists and the importance of patient education during the ongoing Covid-19 pandemic.493cancer,covid,education,pandemic,patientfalsefullhttps://www.spreaker.com/episode/the-variable-acceptance-of-the-covid-vaccine--48425646https://api.spreaker.com/episode/48425646Mon, 24 Jan 2022 15:35:10 +0000cancerGRACEDr. Jack West, Dr. Benjamin Levy, and Dr. Jared Weiss discuss the Covid vaccine in relation to cancer patients.566cancer,covid,patient,vaccinefalsefullhttps://www.spreaker.com/episode/brain-metastases-in-breast-cancer-treatment-options-for-breast-cancer-patients-who-relapse-with-only-cns-metastases--46706340
Treatment Options for Breast Cancer Patients who Relapse with Only CNS Metastases
Dr. Medhavi Gupta

Dr. Nancy Lin]]>https://api.spreaker.com/episode/46706340Sun, 23 Jan 2022 16:00:01 +0000cancerGRACEBrain Metastases in Breast Cancer Treatment Options for Breast Cancer Patients who Relapse with Only CNS Metastases Dr. Medhavi Gupta Dr. Nancy Lin
Treatment Options for Breast Cancer Patients who Relapse with Only CNS Metastases
Dr. Medhavi Gupta

Dr. Nancy Lin]]>370brain,breast,cancer,cancer treatment,cns,metastases,patients,relapsefalsefullhttps://www.spreaker.com/episode/brain-metastases-in-breast-cancer-prognosis-and-impact-on-survival--46706342Patients with Brain Metastases in Breast Cancer - Prognosis and Impact on Survival with Dr. Medhavi Gupta and Dr. Nancy Lin]]>https://api.spreaker.com/episode/46706342Sat, 22 Jan 2022 16:00:02 +0000cancerGRACEBrain Metastases in Breast Cancer - Patients with Brain Metastases in Breast Cancer - Prognosis and Impact on Survival with Dr. Medhavi Gupta and Dr. Nancy LinPatients with Brain Metastases in Breast Cancer - Prognosis and Impact on Survival with Dr. Medhavi Gupta and Dr. Nancy Lin]]>264brain,breast,cancer,metastases,patients,prognosis,survivalfalsefullhttps://www.spreaker.com/episode/melanoma-updates-adjuvant-treatment-options-for-melanoma--48428441Dr. Roman Groisberg discusses options for adjuvant treatment in patients with melanoma.

A huge thank you to our sponsors #Merck and #Exelixis!

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/48428441Fri, 21 Jan 2022 19:24:00 +0000cancerGRACEMeredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for...Dr. Roman Groisberg discusses options for adjuvant treatment in patients with melanoma.

A huge thank you to our sponsors #Merck and #Exelixis!

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>604adjuvant,cancer,cancergrace,melanoma,patients,treatmentfalsefullhttps://www.spreaker.com/episode/metastatic-triple-negative-breast-cancer-immunotherapy-treatment-options-and-potential-side-effects--46706394https://api.spreaker.com/episode/46706394Fri, 21 Jan 2022 16:00:03 +0000cancerGRACEMetastatic Triple Negative Breast Cancer, Immunotherapy Treatment Options and Potential Side Effects with Dr. Medhavi Gupta and Dr. Aditya Bardai702breast,cancer,effects,immunotherapy,metastatic,negative,side,triplefalsefullhttps://www.spreaker.com/episode/recent-data-and-developments-in-palliative-head-and-neck-cancer-treatments--48380226https://api.spreaker.com/episode/48380226Thu, 20 Jan 2022 19:20:55 +0000cancerGRACEIn this episode, Dr. Jared Weiss and Dr. Siddharth Sheth discuss recent updates in palliative care of patients with head and neck cancers.620falsefullhttps://www.spreaker.com/episode/palliative-care-and-studies-for-incurable-head-and-neck-cancers--48380196https://api.spreaker.com/episode/48380196Thu, 20 Jan 2022 19:19:36 +0000cancerGRACEIn this episode, Dr. Jared Weiss and Dr. Siddharth Sheth discuss palliative care for incurable head and neck cancers, and recent studies regarding the subject.693cancer,head,neck,palliativefalsefullhttps://www.spreaker.com/episode/hpv-and-head-and-neck-cancers--48380174https://api.spreaker.com/episode/48380174Thu, 20 Jan 2022 19:17:34 +0000cancerGRACEIn this episode, Dr. Jared Weiss and Dr. Siddharth Sheth discuss the role HPV plays in head and neck cancers.710cancer,head,hpv,neckfalsefullhttps://www.spreaker.com/episode/curative-modalities-and-immunotherapy-for-head-and-neck-cancers--48380088https://api.spreaker.com/episode/48380088Thu, 20 Jan 2022 19:15:38 +0000cancerGRACEIn this episode, Dr. Jared Weiss and Dr. Siddharth Sheth discuss recent developments in curative modalities as well as immunotherapy in head and neck cancers.849cancer,head,neckfalsefullhttps://www.spreaker.com/episode/metastatic-triple-negative-breast-cancer-antibody-drug-conjugate-treatment-options--46706395https://api.spreaker.com/episode/46706395Thu, 20 Jan 2022 16:00:02 +0000cancerGRACEMetastatic Triple-Negative Breast Cancer Antibody-Drug Conjugate Treatment Options with Dr. Medhavi Gupta and Dr. Aditya Bardai657antibody,breast,cancer,conjugate,negative,treatment,triplefalsefullhttps://www.spreaker.com/episode/metastatic-triple-negative-breast-cancer-targeted-therapy-treatment-options-and-potential-side-effects--46706396https://api.spreaker.com/episode/46706396Wed, 19 Jan 2022 16:00:02 +0000cancerGRACEMetastatic Triple Negative Breast Cancer Targeted Therapy Treatment Options and Potential Side Effects with Dr. Medhavi Gupta and Dr. Aditya Bardai667breast,cancer,effects,metastatic,negative,side,targeted,therapy,triplefalsefullhttps://www.spreaker.com/episode/surgical-management-in-breast-cancer-body-image-and-reconstruction-surgery--46706447https://api.spreaker.com/episode/46706447Tue, 18 Jan 2022 16:00:02 +0000cancerGRACESurgical Management in Breast Cancer, Body Image and Reconstruction Surgery with Dr. Medhavi Gupta and Dr. Jessica Young488body,breast,cancer,image,reconstruction,surgeryfalsefullhttps://www.spreaker.com/episode/surgical-management-in-breast-cancer-what-to-expect-during-surgery--46706448https://api.spreaker.com/episode/46706448Mon, 17 Jan 2022 16:05:02 +0000cancerGRACESurgical Management in Breast Cancer, What to Expect During Surgery with Dr. Medhavi Gupta and Dr. Jessica Young383breast,cancer,surgeryfalsefullhttps://www.spreaker.com/episode/surgical-management-in-breast-cancer-long-term-outcomes-breast-conserving-therapy-vs-mastectomy--46706450https://api.spreaker.com/episode/46706450Sun, 16 Jan 2022 16:00:02 +0000cancerGRACESurgical Management in Breast Cancer, Long Term Outcomes - Breast-Conserving Therapy vs. Mastectomy with Dr. Medhavi Gupta and Dr. Jessica Young258breast,cancer,outcomes,surgeryfalsefullhttps://www.spreaker.com/episode/surgical-management-in-breast-cancer-what-to-expect-after-surgery--46706449https://api.spreaker.com/episode/46706449Sun, 16 Jan 2022 16:00:02 +0000cancerGRACESurgical Management in Breast Cancer, What to Expect After Surgery with Dr. Medhavi Gupta and Dr. Jessica Young588breast,cancer,surgeryfalsefullhttps://www.spreaker.com/episode/surgical-management-in-breast-cancer-the-role-of-different-types-of-surgery-and-the-management-of-patients-with-breast-cancer--46706451https://api.spreaker.com/episode/46706451Sat, 15 Jan 2022 16:00:02 +0000cancerGRACESurgical Management in Breast Cancer - The Role of Different Types of Surgery and the Management of Patients with Breast Cancer, with Dr. Medhavi Gupta and Dr. Jessica Young282breast,cancer,management,surgeryfalsefullhttps://www.spreaker.com/episode/surgical-management-in-breast-cancer-prophylactic-mastectomy-on-the-opposite-breast--46706452https://api.spreaker.com/episode/46706452Fri, 14 Jan 2022 16:00:02 +0000cancerGRACESurgical Management in Breast Cancer - Prophylactic Mastectomy on the Opposite Breast with Dr. Medhavi Gupta and Dr. Jessica Young306breast,cancer,mastectomy,surgeryfalsefullhttps://www.spreaker.com/episode/brain-metastases-in-breast-cancer-signs-symptoms-screening-and-treatment-for-brain-metastases-in-breast-cancer--46706341
Signs, Symptoms, Screening and Treatment for Brain Metastases in Breast Cancer with Dr. Medhavi Gupta and Dr. Nancy Lin]]>https://api.spreaker.com/episode/46706341Fri, 14 Jan 2022 02:15:17 +0000cancerGRACEBrain Metastases in Breast Cancer Signs, Symptoms, Screening and Treatment for Brain Metastases in Breast Cancer with Dr. Medhavi Gupta and Dr. Nancy Lin
Signs, Symptoms, Screening and Treatment for Brain Metastases in Breast Cancer with Dr. Medhavi Gupta and Dr. Nancy Lin]]>449brain,breast,cancer,metastases,screening,symptoms,treatmentfalsefullhttps://www.spreaker.com/episode/surgical-management-in-breast-cancer-surgical-removal-of-lymph-nodes-sentinel-lymph-node-biopsy-vs-axillary-lymph-node-dissection-alnd--46706453
Surgical Removal of Lymph Nodes - Sentinel Lymph Node Biopsy vs. Axillary Lymph Node Dissection (ALND) with Dr. Medhavi Gupta and Dr. Jessica Young]]>https://api.spreaker.com/episode/46706453Fri, 14 Jan 2022 01:36:33 +0000cancerGRACESurgical Management in Breast Cancer Surgical Removal of Lymph Nodes - Sentinel Lymph Node Biopsy vs. Axillary Lymph Node Dissection (ALND) with Dr. Medhavi Gupta and Dr. Jessica Young
Surgical Removal of Lymph Nodes - Sentinel Lymph Node Biopsy vs. Axillary Lymph Node Dissection (ALND) with Dr. Medhavi Gupta and Dr. Jessica Young]]>424alnd,biopsy,breast,cancer,dissection,lymph,node,surgeryfalsefullhttps://www.spreaker.com/episode/gracecast-2021-spanish-covid-panel-vacunas-contra-el-covid-en-pacientes-con-cancer--45522639COVID Vaccines in Cancer Patients with Drs. Luis Raez, Estalemari Rodríguez, and Ticiana Leal]]>https://api.spreaker.com/episode/45522639Sat, 25 Sep 2021 00:00:12 +0000cancerGRACEVacunas contra el COVID en pacientes con cancer con los Dres. Luis Raez, Estalemari Rodríguez, y Ticiana Leal COVID Vaccines in Cancer Patients with Drs. Luis Raez, Estalemari Rodríguez, and Ticiana LealCOVID Vaccines in Cancer Patients with Drs. Luis Raez, Estalemari Rodríguez, and Ticiana Leal]]>741cancer,covid,spanish,vaccinefalsefullhttps://www.spreaker.com/episode/gracecast-2021-spanish-covid-panel-usos-de-la-telemedicina-para-pacientes-con-cancer--45522640
Uses of Telemedicine for the treatment of cancer patients with Drs. Luis Raez, Estalemari Rodríguez, and Ticiana Leal]]>https://api.spreaker.com/episode/45522640Thu, 23 Sep 2021 23:30:10 +0000cancerGRACEUsos de la Telemedicina para el tratamiento de pacientes con cancer con los Dres. Luis Raez, Estalemari Rodríguez, y Ticiana Leal Uses of Telemedicine for the treatment of cancer patients with Drs. Luis Raez, Estalemari Rodríguez, and Ticiana Leal
Uses of Telemedicine for the treatment of cancer patients with Drs. Luis Raez, Estalemari Rodríguez, and Ticiana Leal]]>713cancer,covid,spanish,telemedicinefalsefullhttps://www.spreaker.com/episode/gracecast-spanish-covid-panel-impacto-de-la-covid-19-en-la-atencion-de-pacientes-con-cancer--45522641Impact of the Covid-19 Pandemic on caring for cancer patients with Drs. Luis Raez, Estalemari Rodríguez, and Ticiana Leal]]>https://api.spreaker.com/episode/45522641Wed, 22 Sep 2021 23:00:10 +0000cancerGRACEImpacto de la Pandemia del Covid-19 en el cuidado de enfermos de cancer con los Dres. Luis Raez, Estalemari Rodríguez, y Ticiana Leal Impact of the Covid-19 Pandemic on caring for cancer patients with Drs. Luis Raez, Estalemari Rodríguez, and Ticiana LealImpact of the Covid-19 Pandemic on caring for cancer patients with Drs. Luis Raez, Estalemari Rodríguez, and Ticiana Leal]]>446cancer,covid,pandemic,spanishfalsefullhttps://www.spreaker.com/episode/gracecast-podcast-2021-english-q1-covid-panel-covid-19-variants-and-the-challenge-for-cancer-care--45522637
COVID-19 Variants and the Challenge for Cancer Care

Drs. H. Jack West, Jared Weiss, and Ben Levy, members of the GRACE Board of Directors, discuss the changes and challenges of consistent cancer care during the COVID -19.]]>https://api.spreaker.com/episode/45522637Tue, 21 Sep 2021 02:30:04 +0000cancerGRACEFirst Quarter 2021 Panel COVID-19 Variants and the Challenge for Cancer Care Drs. H. Jack West, Jared Weiss, and Ben Levy, members of the GRACE Board of Directors, discuss the changes and challenges of consistent cancer care during the COVID -19.
COVID-19 Variants and the Challenge for Cancer Care

Drs. H. Jack West, Jared Weiss, and Ben Levy, members of the GRACE Board of Directors, discuss the changes and challenges of consistent cancer care during the COVID -19.]]>483cancer,covid,variantsfalsefullhttps://www.spreaker.com/episode/gracecast-podcast-2021-english-q1-covid-panel-what-patients-should-expect-post-covid-19-vaccination--45522635
What Patients Should Expect Post COVID-19 Vaccination

Drs. H. Jack West, Jared Weiss, and Ben Levy, members of the GRACE Board of Directors, discuss the changes and challenges of consistent cancer care during the COVID -19.]]>https://api.spreaker.com/episode/45522635Tue, 21 Sep 2021 02:00:04 +0000cancerGRACEFirst Quarter 2021 Panel What Patients Should Expect Post COVID-19 Vaccination Drs. H. Jack West, Jared Weiss, and Ben Levy, members of the GRACE Board of Directors, discuss the changes and challenges of consistent cancer care during the COVID -19.
What Patients Should Expect Post COVID-19 Vaccination

Drs. H. Jack West, Jared Weiss, and Ben Levy, members of the GRACE Board of Directors, discuss the changes and challenges of consistent cancer care during the COVID -19.]]>488cancer,covid,vaccinefalsefullhttps://www.spreaker.com/episode/gracecast-podcast-2021-english-q1-covid-panel-the-continued-use-of-telemedicine-in-cancer-treatment--45522634
The Continued Use of Telemedicine in Cancer Treatment

Drs. H. Jack West, Jared Weiss, and Ben Levy, members of the GRACE Board of Directors, discuss the changes and challenges of consistent cancer care during the COVID -19.]]>https://api.spreaker.com/episode/45522634Tue, 21 Sep 2021 01:30:02 +0000cancerGRACEFirst Quarter 2021 Panel The Continued Use of Telemedicine in Cancer Treatment Drs. H. Jack West, Jared Weiss, and Ben Levy, members of the GRACE Board of Directors, discuss the changes and challenges of consistent cancer care during the COVID -19.
The Continued Use of Telemedicine in Cancer Treatment

Drs. H. Jack West, Jared Weiss, and Ben Levy, members of the GRACE Board of Directors, discuss the changes and challenges of consistent cancer care during the COVID -19.]]>885cancer,covid,telemedicinefalsefullhttps://www.spreaker.com/episode/gracecast-podcast-2021-english-q1-covid-panel-is-the-covid-19-vaccine-safe-for-cancer-patients--45522638
Is the COVID-19 Vaccine Safe For Cancer Patients

GRACE 2021 Panel, Changes and Challenges of Consistent Cancer Care During the Ongoing Pandemic

Drs. H. Jack West, Jared Weiss and Ben Levy, members of the GRACE Board of Directors, discuss the changes and challenges of consistent cancer care during the COVID -19.]]>https://api.spreaker.com/episode/45522638Tue, 21 Sep 2021 01:00:02 +0000cancerGRACEFirst Quarter 2021 Panel Is the COVID-19 Vaccine Safe For Cancer Patients GRACE 2021 Panel, Changes and Challenges of Consistent Cancer Care During the Ongoing Pandemic Drs. H. Jack West, Jared Weiss and Ben Levy, members of the GRACE Board of...
Is the COVID-19 Vaccine Safe For Cancer Patients

GRACE 2021 Panel, Changes and Challenges of Consistent Cancer Care During the Ongoing Pandemic

Drs. H. Jack West, Jared Weiss and Ben Levy, members of the GRACE Board of Directors, discuss the changes and challenges of consistent cancer care during the COVID -19.]]>584cancer,covidfalsefullhttps://www.spreaker.com/episode/gracecast-2021-covid-panel-changes-and-challenges-of-consistent-cancer-care-during-the-pandemic--45522636
Drs. H. Jack West, Jared Weiss and Ben Levy, members of the GRACE Board of Directors, discuss the changes and challenges of consistent cancer care during the COVID -19.]]>https://api.spreaker.com/episode/45522636Sat, 03 Jul 2021 15:00:16 +0000cancerGRACEGRACE 2021 Panel, Changes and Challenges of Consistent Cancer Care During the Ongoing Pandemic Drs. H. Jack West, Jared Weiss and Ben Levy, members of the GRACE Board of Directors, discuss the changes and challenges of consistent cancer care during...
Drs. H. Jack West, Jared Weiss and Ben Levy, members of the GRACE Board of Directors, discuss the changes and challenges of consistent cancer care during the COVID -19.]]>464cancer,cancercare,covid,pandemicfalsefullhttps://www.spreaker.com/episode/gracecast-2021-covid-panel-covid-19-pandemic-and-the-impact-on-cancer-care--45522633
Drs. H. Jack West, Jared Weiss and Ben Levy, members of the GRACE Board of Directors, discuss the impact the COVID -19 pandemic has had on cancer care.]]>https://api.spreaker.com/episode/45522633Thu, 01 Jul 2021 17:40:09 +0000cancerGRACEGRACE 2021 Panel, Trends & Implications - The COVID-19 Pandemic Impact on Cancer Care Drs. H. Jack West, Jared Weiss and Ben Levy, members of the GRACE Board of Directors, discuss the impact the COVID -19 pandemic has had on cancer care.
Drs. H. Jack West, Jared Weiss and Ben Levy, members of the GRACE Board of Directors, discuss the impact the COVID -19 pandemic has had on cancer care.]]>444cancer,covid,pandemic,treatmentfalsefullhttps://www.spreaker.com/episode/gracecast-are-there-alternatives-to-radiation-for-patients-with-brain-metastases--24827822https://api.spreaker.com/episode/24827822Wed, 16 Jun 2021 15:00:05 +0000cancerGRACEDr. Johathan Riess joins GRACE to discuss alternatives to radiation for patients with brain metastases.419brain,cancer,cancergrace,lung,metastasis,nsclc,treatmentfalsefullhttps://www.spreaker.com/episode/gracecast-what-is-the-optimal-treatment-for-patients-with-advanced-nsclc-and-a-braf-v600e-mutation--24827823https://api.spreaker.com/episode/24827823Wed, 09 Jun 2021 15:00:07 +0000cancerGRACEDr. Caroline McCoach joins GRACE to discuss optimal treatment for patients with advanced non small cell lung cancer and a BRAF-V600 mutation.335braf,cancer,cancergrace,lung,nsclc,treatmentfalsefullhttps://www.spreaker.com/episode/gracecast-what-is-tumor-mutational-burden-tmb-and-could-it-be-helpful-in-lung-cancer-management-today--24827824https://api.spreaker.com/episode/24827824Wed, 02 Jun 2021 15:00:12 +0000cancerGRACEDr. Matthew Gubens joins GRACE to discuss Tumor Mutational Burden in NSCLC.310burden,cancer,lung,mutational,nsclc,tmb,treatment,tumorfalsefullhttps://www.spreaker.com/episode/gracecast-treatment-options-for-metastatic-nsclc--24827825https://api.spreaker.com/episode/24827825Wed, 26 May 2021 15:00:20 +0000cancerGRACEDr. Heather Wakelee joins GRACE to discuss treatment options for a metastatic non small cell lung cancer diagnosis.558cancer,lung,metastatic,nsclc,treatmentfalsefullhttps://www.spreaker.com/episode/gracecast-are-there-treatment-options-for-patients-with-her-2-nsclc--24827826https://api.spreaker.com/episode/24827826Thu, 20 May 2021 17:51:35 +0000cancerGRACEMillie Das, MD Joins GRACE to discuss treatment options for patients with HER-2 NSCLC359cancer,her-2,lung,nsclc,treatmentfalsefullhttps://www.spreaker.com/episode/podcast-gracecast-dr-sandip-patel-emerging-molecular-targets-in-nsclc-kras--40255540https://api.spreaker.com/episode/40255540Wed, 12 May 2021 15:00:04 +0000cancerGRACEDr. Sandip Patel discusses emerging Molecular Targets in NSCLC- KRAS391emerging,kras,molecular,nsclc,targetsfalsefullhttps://www.spreaker.com/episode/gracecast-dr-sandip-patel-emerging-molecular-targets-in-nsclc-egfr-exon-20--40255541https://api.spreaker.com/episode/40255541Wed, 05 May 2021 15:00:08 +0000cancerGRACEDr. Sandip Patel discusses emerging molecular targets in NSCLC -- EGFR Exon 20404egfr,exon,molecular,nsclc,targetsfalsefullhttps://www.spreaker.com/episode/gracecast-asco-lung-2020-enhertu-and-the-potential-for-treatment-of-her2-positive-nsclc--40255626https://api.spreaker.com/episode/40255626Wed, 28 Apr 2021 15:00:15 +0000cancerGRACEDrs. H. Jack West, Helena Yu and David Spigel discuss Enhertu and the Potential for Treatment of HER2 Positive NSCLC.581falsefullhttps://www.spreaker.com/episode/gracecast-asco-lung-2020-the-sindas-trial-the-addition-of-sbrt-to-a-systemic-egfr-inhibitor-tki-in-egfr-positive-nsclc--40255627https://api.spreaker.com/episode/40255627Wed, 21 Apr 2021 15:00:21 +0000cancerGRACEDrs. H. Jack West, Helena Yu and David Spigel discuss The SINDAS Trial - The Addition of SBRT to a Systemic EGFR inhibitor TKI in EGFR positive NSCLC811egfr,nsclc,sbrt,sindasfalsefullhttps://www.spreaker.com/episode/gracecast-asco-lung-2020-new-potential-treatments-for-met-and-ret-positive-nsclc-capmatinib-tabrecta-and-blu-667-pralsetinib--40255628https://api.spreaker.com/episode/40255628Wed, 14 Apr 2021 23:30:22 +0000cancerGRACEDrs. H. Jack West, David Spigel and Helena Yu discuss new potenteial treatments for MET and RET Positive NSCLC: Capmatinib/Tabrecta and BLU-667/Pralsetinib619cancer,lung,met,nsclc,ret,treatmentfalsefullhttps://www.spreaker.com/episode/gracecast-lcvl-can-egfr-inhibitor-therapy-treat-and-prevent-brain-metastases--24827827https://api.spreaker.com/episode/24827827Wed, 31 Mar 2021 15:00:14 +0000cancerGRACEDr. H. Jack West discusses if EGFR Inhibitor therapy can treat and prevent brain metastases538brain,cancer,egfr,lung,metastasesfalsefullhttps://www.spreaker.com/episode/gracecast-lcvl-what-are-the-options-after-a-patient-with-an-alk-positive-advanced-nsclc-develops-resistance-on-alecensa-alectinib--24827828https://api.spreaker.com/episode/24827828Wed, 24 Mar 2021 15:00:18 +0000cancerGRACEDr. Caroline McCoach discusses What are the options after a patient with an ALK-positive advanced NSCLC develops resistance on Alecensa-alectinib342alecensa,alectinib,alk,cancer,lung,resistancefalsefullhttps://www.spreaker.com/episode/gracecast-lcvl-can-immunotherapy-help-frail-patients-with-advanced-nsclc--24827829https://api.spreaker.com/episode/24827829Wed, 17 Mar 2021 15:00:18 +0000cancerGRACEDr. Matthew Gubens discusses Can immunotherapy help frail patients with advanced NSCLC324cancer,frail,immunotherapy,lung,nsclcfalsefullhttps://www.spreaker.com/episode/gracecast-lcvl-what-is-the-role-of-immunotherapy-for-unresectable-stage-3-nsclc-today--24827830https://api.spreaker.com/episode/24827830Fri, 12 Mar 2021 00:51:40 +0000cancerGRACEGRACECast - LCVL Dr. Millie Das discusses What is the role of immunotherapy for unresectable Stage 3 NSCLC today227falsefullhttps://www.spreaker.com/episode/gracecast-lcvl-h-jack-west-md-can-alk-inhibitors-treat-and-prevent-brain-metastases--24827831https://api.spreaker.com/episode/24827831Fri, 12 Mar 2021 00:49:11 +0000cancerGRACEDr. Howard Jack West discusses ALK Rearrangement-Positive NSCLC and if ALK inhibitors treat and prevent brain metastases?461alk,brain,cancer,cancergrace,lung,metastasesfalsefullhttps://www.spreaker.com/episode/gracecast-lcvl-can-blood-based-mutation-testing-help-shape-treatment-decisions-for-advanced-nsclc--24827832https://api.spreaker.com/episode/24827832Wed, 24 Feb 2021 16:00:17 +0000cancerGRACEDr. Heather Wakelee discusses whether blood-based mutation-testing can help shape treatment decisions for advanced NSCLC.460cancer,cancergrace,lung,mutation,nsclc,testingfalsefullhttps://www.spreaker.com/episode/gracecast-lcvl-consolidation-immunotherapy-after-chemo-radiation-for-stage-3-unresectable-nsclc--24827834https://api.spreaker.com/episode/24827834Wed, 17 Feb 2021 16:00:20 +0000cancerGRACEDr. Heather Wakelee discusses which patients should receive consolidation immunotherapy after chemo radiation for stage 3 unresectable non small cell lung cancer.475cancer,cancergrace,chemotherapy,immunotherapy,lung,nsclc,radiationfalsefullhttps://www.spreaker.com/episode/gracecast-lcvl-can-local-therapies-improve-outcomes-for-stage-iv-nsclc--24827833https://api.spreaker.com/episode/24827833Tue, 16 Feb 2021 22:15:21 +0000cancerGRACEDr. H. Jack West discusses if local therapies improve outcomes for patients with stage IV NSCLC who have a very good response to first line systemic therapy489cancer,cancergrace,chemotherapy,local,lung,nsclc,therapyfalsefullhttps://www.spreaker.com/episode/gracecast-lcvl-could-pre-operative-immunotherapy-improve-outcomes-in-early-stage-nsclc--24827843https://api.spreaker.com/episode/24827843Wed, 03 Feb 2021 16:00:21 +0000cancerGRACEDr. Joel Neal discusses pre-operative immunotherapy and if it could improve outcomes in early stage NSCLC. Why trials are looking at this approach.569cancer,cancergrace,clinicaltrials,immunotherapy,lung,nsclcfalsefullhttps://www.spreaker.com/episode/gracecast-lcvl-leading-treatment-options-for-patients-with-low-or-negative-tumor-pd-l1-expression-and-advanced-nonsquamous-nsclc-today--24827842https://api.spreaker.com/episode/24827842Wed, 27 Jan 2021 16:00:03 +0000cancerGRACEDr. Millie Das discusses the leading treatment options for patients with low or negative tumor PD-L1 expression and advanced nonsquamous NSCLC today.519cancer,cancergrace,lung,nonsquamous,nsclc,pdl-1falsefullhttps://www.spreaker.com/episode/gracecast-lcvl-can-patients-with-an-egfr-mutation-positive-advanced-nsclc-benefit-from-immunotherapy--24827841https://api.spreaker.com/episode/24827841Wed, 20 Jan 2021 16:00:09 +0000cancerGRACEDr. Dr. Joel Neal discusses patients with an EGFR mutation positive advanced non small cell lung cancer and if they can benefit from immunotherapy.639cancer,cancergrace,immunotherapy,lung,nsclcfalsefullhttps://www.spreaker.com/episode/gracecast-lcvl-what-are-the-leading-first-line-treatment-options-for-advanced-nsclc-harboring-an-alk-rearrangement-today--24827840https://api.spreaker.com/episode/24827840Wed, 30 Dec 2020 16:00:21 +0000cancerGRACEDr. Caroline McCoach discusses ALK Rearrangement-Positive NSCLC and the leading first line treatment options for advanced NSCLC harboring an ALK rearrangement today277alk,cancer,cancergrace,lung,nsclc,treatmentfalsefullhttps://www.spreaker.com/episode/gracecast-lcvl-can-immunotherapy-help-patients-with-small-cell-lung-cancer--24827839https://api.spreaker.com/episode/24827839Wed, 23 Dec 2020 16:00:17 +0000cancerGRACEDr. Joel Neal discusses Small Cell Lung Cancer and whether or not immunotherapy can help patients with small cell lung cancer665cancer,cancergrace,cell,immunotherapy,lung,sclc,smallfalsefullhttps://www.spreaker.com/episode/gracecast-lcvl-leading-treatment-options-for-patients-with-low-or-negative-tumor-pd-l1-expression-and-advanced-squamous-nsclc-today--24827838https://api.spreaker.com/episode/24827838Wed, 16 Dec 2020 16:00:09 +0000cancerGRACEDr. Matthew Gubens discusses Targeted therapies in NSCLC PD-L1 Expression and the leading treatment options for patients with low or negative tumor PD-L1 expression and advanced squamous NSCLC today412cancer,cancergrace,lung,nsclc,pdl1,squamous,targeted,therapyfalsefullhttps://www.spreaker.com/episode/gracecast-lcvl-what-is-the-best-first-line-treatment-for-patients-with-advanced-egfr-mutation-positive-nsclc-today--24827837https://api.spreaker.com/episode/24827837Wed, 09 Dec 2020 16:00:21 +0000cancerGRACEDr. Jonathan Reiss discusses EGFR Mutation and the best first line treatment for patients with advanced EGFR mutation-positive NSCLC today391cancer,cancergrace,egfr,lung,nsclc,treatmentfalsefullhttps://www.spreaker.com/episode/gracecast-lcvl-which-patients-with-advanced-nsclc-are-good-candidates-for-first-line-immunotherapy-alone-today--24827835https://api.spreaker.com/episode/24827835Wed, 02 Dec 2020 16:00:14 +0000cancerGRACEDr H. Jack West discusses Immunotherapy in NSCLC, and which patients with advanced NSCLC are good candidates for first line immunotherapy alone today?566cancer,cancergrace,firstline,immunotherapy,lung,nsclcfalsefullhttps://www.spreaker.com/episode/gracecast-lcvl-what-is-the-current-standard-of-care-for-patients-with-extensive-stage-small-cell-lung-cancer--24827836https://api.spreaker.com/episode/24827836Wed, 25 Nov 2020 16:00:08 +0000cancerGRACEDr. Jonathan Reiss discusses the current standard of care for patients with extensive stage small cell lung cancer.358cancer,cancergrace,lung,sclc,smallcelllungcancer,treatmentfalsefullhttps://www.spreaker.com/episode/gracecast-treatment-options-for-patients-with-nsclc-and-high-tumor-pd-l1-expression--24827846https://api.spreaker.com/episode/24827846Wed, 18 Nov 2020 16:00:28 +0000cancerGRACEDr. Millie Das discusses leading treatment options for patients with non small cell lung cancer and hugh tumor PDL1 expression589cancer,cancergrace,lung,nsclc,pdl1,treatmentfalsefullhttps://www.spreaker.com/episode/gracecast-treatment-options-for-patients-with-advanced-nsclc-and-a-her2-erbb2-mutation--24827845https://api.spreaker.com/episode/24827845Wed, 11 Nov 2020 16:00:10 +0000cancerGRACEDr. Millie Das discusses treatment options for patients with advanced non small cell lung cancer and a HER2-ERBB2 mutation.391cancer,cancergrace,erbb2,her2,lung,nsclc,treatmentfalsefullhttps://www.spreaker.com/episode/gracecast-does-immunotherapy-have-activity-in-malignant-pleural-mesothelioma--24827844https://api.spreaker.com/episode/24827844Wed, 04 Nov 2020 16:00:09 +0000cancerGRACEDr. Millie Das discusses whether immunotherapy has activity in malignant pleural mesothelioma.371immunotherapy,mesotheliomafalsefullhttps://www.spreaker.com/episode/gracecast-leading-treatment-options-for-patients-with-negative-tumor-pd-l1-nsclc-with-dr-stephen-liu--40255539
For more information visit www.cancerGRACE.org]]>https://api.spreaker.com/episode/40255539Wed, 28 Oct 2020 15:00:16 +0000cancerGRACEDr. Stephen Liu, member of the GRACE faculty, discusses leading treatment options for patients with negative tumor pdl-1 in non small cell lung cancer. For more information visit www.cancerGRACE.org
For more information visit www.cancerGRACE.org]]>416cancer,cancergrace,cancertreatment,lung,nsclc,pdl1,tumorfalsefullhttps://www.spreaker.com/episode/gracecast-immunotherapy-for-small-cell-lung-cancer-with-dr-stephen-liu--40255538
For more information visit www.cancerGRACE.org]]>https://api.spreaker.com/episode/40255538Wed, 21 Oct 2020 15:00:13 +0000cancerGRACEDr. Stephen Liu, member of the GRACE faculty, discusses immunotherapy for small cell lung cancer. For more information visit www.cancerGRACE.org
For more information visit www.cancerGRACE.org]]>483cancergrace,cancertreatment,cell,immunotherapy,lungcancer,sclc,smallfalsefullhttps://www.spreaker.com/episode/gracecast-emerging-molecular-targets-in-nsclc-ret-fusions-with-dr-josh-bauml--40255537
For more information visit www.cancerGRACE.org]]>https://api.spreaker.com/episode/40255537Wed, 14 Oct 2020 15:00:16 +0000cancerGRACEDr. Josh Bauml, member of the GRACE faculty, discusses emerging molecular targets in non small cell lung cancer for RET fusions. For more information visit www.cancerGRACE.org
For more information visit www.cancerGRACE.org]]>381cancergrace,cancertreatment,lungcancer,molecular,nsclc,ret,targetsfalsefullhttps://www.spreaker.com/episode/gracecast-emerging-molecular-targets-in-nsclc-met-with-dr-josh-bauml--40255536
for more information visit www.cancerGRACE.org]]>https://api.spreaker.com/episode/40255536Wed, 07 Oct 2020 15:00:14 +0000cancerGRACEDr. Josh Bauml, member of the GRACE faculty, discusses emerging molecular targets in non small cell lung cancer with a MET mutation. for more information visit www.cancerGRACE.org
for more information visit www.cancerGRACE.org]]>424cancergrace,cancertreatment,lungcancer,met,moleculartargets,nsclcfalsefullhttps://www.spreaker.com/episode/gracecast-2020-updates-in-small-cell-lung-cancer-with-dr-jared-weiss--40255300
For more info, visit www.cancerGRACE.org]]>https://api.spreaker.com/episode/40255300Wed, 30 Sep 2020 15:00:20 +0000cancerGRACEDr. Jared Weiss, GRACE VP on the Board of Directors and Faculty for GRACE discusses updates for the treatment of Small Cell Lung Cancer. For more info, visit www.cancerGRACE.org
For more info, visit www.cancerGRACE.org]]>455cancergrace,cancertreatment,lungcancer,sclc,smallcellfalsefullhttps://www.spreaker.com/episode/gracecast-2020-new-tkis-for-stage-iv-non-small-cell-lung-cancer-mutations-with-dr-jared-weiss--40255299https://api.spreaker.com/episode/40255299Wed, 23 Sep 2020 15:00:21 +0000cancerGRACEDr. Jared Weiss, Vice President of the GRACE Board of Directors and GRACE faculty, discusses the new TKIs for Stage IV Non Small Cell Lung Cancer mutations including MET, RET, and HER2.346her2,lungcancer,met,nsclc,ret,tkifalsefullhttps://www.spreaker.com/episode/gracecast-2020-treatment-option-explored-in-the-adaura-trial-with-dr-jared-weiss--40255298https://api.spreaker.com/episode/40255298Mon, 21 Sep 2020 23:37:45 +0000cancerGRACEDr. Jared Weiss, Vice President of the GRACE Board of Directors and GRACE faculty, discusses the ADAURA trial; the first global trial for an EGFR inhibitor to show statistically significant and clinically meaningful benefit in adjuvant treatment of...349audura,cancergrace,clinical,lungcancer,nsclc,osimertinib,trialfalsefullhttps://www.spreaker.com/episode/case-based-panel-discussion-egfr-mutation-patient-progression-and-next-steps--24526031Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.

In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds patient progression in a case with EGFR mutation, and what are the next steps.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/24526031Wed, 09 Sep 2020 15:00:19 +0000cancerGRACEFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach. Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center. Dr. McCoach is...Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.

In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds patient progression in a case with EGFR mutation, and what are the next steps.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>552cancer,egfr,lung,nsclc,progression,treatmentfalsefullhttps://www.spreaker.com/episode/case-based-panel-discussion-egfr-mutation-and-high-pdl1-what-is-the-role-of-immunotherapy-in-treatment-decisions--24525945Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.

In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds a case with an EGFR Mutation and High PDL1. The discussion centers around the role of immunotherapy in treatment decisions.


For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/24525945Wed, 02 Sep 2020 15:00:03 +0000cancerGRACEFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach. Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center. Dr. McCoach is...Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.

In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds a case with an EGFR Mutation and High PDL1. The discussion centers around the role of immunotherapy in treatment decisions.


For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>306egfr,immunotherapy,lungcancer,nsclc,pdl1,treatmentfalsefullhttps://www.spreaker.com/episode/case-based-panel-discussion-egfr-mutation-with-met-amplification-treatment-decisions-and-the-importance-of-the-level-of-met-amplification--24525942Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.

In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds an EGFR mutation with MET amplification. They review treatment decisions and the importance of the level of MET amplification.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/24525942Wed, 26 Aug 2020 15:00:17 +0000cancerGRACEFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach. Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center. Dr. McCoach is...Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.

In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds an EGFR mutation with MET amplification. They review treatment decisions and the importance of the level of MET amplification.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>412cancer,egfr,lungcancer,met,nsclc,treatmentfalsefullhttps://www.spreaker.com/episode/webside-discussions-update-pt-3-challenges-and-the-future-for-in-person-patient-care--39788511GRACE Board Members Drs. H. Jack West, Jared Weiss and Ben Levy discuss cancer and Covid-19 and how the ongoing pandemic is effecting in person patient care.

Part 1 - How Has the Coronavirus Pandemic Changed Cancer Management in Patient Care
Part 2 - Update on the Use of Telemedicine in Patient Care During the Pandemic
Part 3 - Challenges and the Future Outlook for In Person Patient Care

To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/39788511Wed, 19 Aug 2020 15:00:18 +0000cancerGRACEIn part three of this three part video series update, presented in July of 2020, GRACE Faculty and Members of the Board of Directors continue their candid discussions regarding cancer and Covid-19. GRACE Board Members Drs. H. Jack West, Jared Weiss...GRACE Board Members Drs. H. Jack West, Jared Weiss and Ben Levy discuss cancer and Covid-19 and how the ongoing pandemic is effecting in person patient care.

Part 1 - How Has the Coronavirus Pandemic Changed Cancer Management in Patient Care
Part 2 - Update on the Use of Telemedicine in Patient Care During the Pandemic
Part 3 - Challenges and the Future Outlook for In Person Patient Care

To join the conversation, visit https://cancergrace.org/forum.]]>741cancergrace,cancertreatment,coronavirus,covid19,patient,patientcare,treatmentfalsefullhttps://www.spreaker.com/episode/webside-discussions-update-pt-2-update-on-the-use-of-telemedicine-in-patient-care-during-the-pandemic--39788512GRACE Board Members Drs. H. Jack West, Jared Weiss and Ben Levy have another candid discussion regarding cancer and Covid-19 and how the ongoing pandemic is effecting patient care. In this series update, we discuss an update on the use of telemedicine in patient care during the pandemic.

Part 1 - How Has the Coronavirus Pandemic Changed Cancer Management in Patient Care
Part 2 - Update on the Use of Telemedicine in Patient Care During the Pandemic
Part 3 - Challenges and the Future Outlook for In Person Patient Care

To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/39788512Wed, 12 Aug 2020 15:00:11 +0000cancerGRACEIn part two of this three part video series update, presented in July of 2020, GRACE Faculty and Members of the Board of Directors continue their candid discussions regarding cancer and Covid-19. GRACE Board Members Drs. H. Jack West, Jared Weiss and...GRACE Board Members Drs. H. Jack West, Jared Weiss and Ben Levy have another candid discussion regarding cancer and Covid-19 and how the ongoing pandemic is effecting patient care. In this series update, we discuss an update on the use of telemedicine in patient care during the pandemic.

Part 1 - How Has the Coronavirus Pandemic Changed Cancer Management in Patient Care
Part 2 - Update on the Use of Telemedicine in Patient Care During the Pandemic
Part 3 - Challenges and the Future Outlook for In Person Patient Care

To join the conversation, visit https://cancergrace.org/forum.]]>995cancergrace,coronavirus,covid19,patientcare,telemedicinefalsefullhttps://www.spreaker.com/episode/webside-discussion-update-part-1-how-has-the-coronavirus-pandemic-changed-cancer-management-in-patient-care--39788510GRACE Board Members Drs. H. Jack West, Jared Weiss and Ben Levy have another candid discussion regarding cancer and Covid-19 and how the ongoing pandemic is effecting patient care. In this series update, we discuss changes to management in patient care, the use of telemedicine and future challenges, as well as other issues relating to a cancer diagnosis in the middle of a pandemic.

Part 1 - How Has the Coronavirus Pandemic Changed Cancer Management in Patient Care
Part 2 - Update on the Use of Telemedicine in Patient Care During the Pandemic
Part 3 - Challenges and the Future Outlook for In Person Patient Care

To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/39788510Wed, 05 Aug 2020 15:00:01 +0000cancerGRACEIn part one of this three part video series update, presented in July of 2020, GRACE Faculty and Members of the Board of Directors continue their candid discussions regarding cancer and Covid-19. GRACE Board Members Drs. H. Jack West, Jared Weiss and...GRACE Board Members Drs. H. Jack West, Jared Weiss and Ben Levy have another candid discussion regarding cancer and Covid-19 and how the ongoing pandemic is effecting patient care. In this series update, we discuss changes to management in patient care, the use of telemedicine and future challenges, as well as other issues relating to a cancer diagnosis in the middle of a pandemic.

Part 1 - How Has the Coronavirus Pandemic Changed Cancer Management in Patient Care
Part 2 - Update on the Use of Telemedicine in Patient Care During the Pandemic
Part 3 - Challenges and the Future Outlook for In Person Patient Care

To join the conversation, visit https://cancergrace.org/forum.]]>976cancergrace,cancertreatment,coronavirus,covid19falsefullhttps://www.spreaker.com/episode/case-based-panel-discussion-what-is-the-recommended-treatment-for-common-egfr-mutations--24525941Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.

In this series, the doctors discuss a series of cases related to EGFR Mutations. In this discussion they review the recommended treatment for a common EGFR mutation.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/24525941Wed, 29 Jul 2020 15:00:10 +0000cancerGRACEFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach. Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center. Dr. McCoach is...Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.

In this series, the doctors discuss a series of cases related to EGFR Mutations. In this discussion they review the recommended treatment for a common EGFR mutation.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>370cancer,cancergrace,egfr,lung,nsclc,treatmentfalsefullhttps://www.spreaker.com/episode/case-based-panel-discussion-egfr-mutation-treated-with-tagrisso-progression-while-on-treatment-and-what-is-the-role-of-repeat-biopsy--24525938Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.

In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds an EGFR mutation treated with Tagrisso, and progression while on treatment.
The doctors also discuss the role of repeat biopsy.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/24525938Wed, 22 Jul 2020 15:00:03 +0000cancerGRACEFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach. Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center. Dr. McCoach is...Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.

In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds an EGFR mutation treated with Tagrisso, and progression while on treatment.
The doctors also discuss the role of repeat biopsy.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>277biopsy,cancer,egfr,lung,nsclc,progression,tagrissofalsefullhttps://www.spreaker.com/episode/webside-manner-remote-delivery-of-medical-info-and-care-rapid-expansion-of-telemedicine-part-3--25579573
In this time of social distancing and limiting clinic exposure, the sudden need for telemedicine and web consults is perhaps changing the future of medicine on a faster pace than we have previously thought possible. In this three part series the doctors discuss a wide range of topics surrounding the use of telemedicine and potential challenges for providers and patients alike.

Does this new process create new helpful tools?
How does the informality of online visits affect the Doctor/Patient relationship?
Are there limitations to telemedicine - when and who is it good for, does it disrupt the ritualization of doctor/patient visits, and the ability to assess the patient?
Is it sustainable?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/25579573Wed, 15 Jul 2020 15:00:06 +0000cancerGRACEIn April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy had a candid discussion regarding telemedicine in the time of the current pandemic. In this time of social distancing and limiting clinic exposure, the sudden...
In this time of social distancing and limiting clinic exposure, the sudden need for telemedicine and web consults is perhaps changing the future of medicine on a faster pace than we have previously thought possible. In this three part series the doctors discuss a wide range of topics surrounding the use of telemedicine and potential challenges for providers and patients alike.

Does this new process create new helpful tools?
How does the informality of online visits affect the Doctor/Patient relationship?
Are there limitations to telemedicine - when and who is it good for, does it disrupt the ritualization of doctor/patient visits, and the ability to assess the patient?
Is it sustainable?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>869cancer,coronavirus,covid19,telehealthfalsefullhttps://www.spreaker.com/episode/webside-manner-remote-delivery-of-medical-info-and-care-rapid-expansion-of-telemedicine-part-2--25579574
In this time of social distancing and limiting clinic exposure, the sudden need for telemedicine and web consults is perhaps changing the future of medicine on a faster pace than we have previously thought possible. In this three part series the doctors discuss a wide range of topics surrounding the use of telemedicine and potential challenges for providers and patients alike.

Does this new process create new helpful tools?
How does the informality of online visits affect the Doctor/Patient relationship?
Are there limitations to telemedicine - when and who is it good for, does it disrupt the ritualization of doctor/patient visits, and the ability to assess the patient?
Is it sustainable?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/25579574Wed, 08 Jul 2020 15:00:15 +0000cancerGRACEIn April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy had a candid discussion regarding telemedicine in the time of the current pandemic. In this time of social distancing and limiting clinic exposure, the sudden...
In this time of social distancing and limiting clinic exposure, the sudden need for telemedicine and web consults is perhaps changing the future of medicine on a faster pace than we have previously thought possible. In this three part series the doctors discuss a wide range of topics surrounding the use of telemedicine and potential challenges for providers and patients alike.

Does this new process create new helpful tools?
How does the informality of online visits affect the Doctor/Patient relationship?
Are there limitations to telemedicine - when and who is it good for, does it disrupt the ritualization of doctor/patient visits, and the ability to assess the patient?
Is it sustainable?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>574cancer,coronavirus,covid19,telehealthfalsefullhttps://www.spreaker.com/episode/webside-manner-remote-delivery-of-medical-info-and-care-rapid-expansion-of-telemedicine-part-1--25579572
In this time of social distancing and limiting clinic exposure, the sudden need for telemedicine and web consults is perhaps changing the future of medicine on a faster pace than we have previously thought possible. In this three part series the doctors discuss a wide range of topics surrounding the use of telemedicine and potential challenges for providers and patients alike.

Does this new process create new helpful tools?
How does the informality of online visits affect the Doctor/Patient relationship?
Are there limitations to telemedicine - when and who is it good for, does it disrupt the ritualization of doctor/patient visits, and the ability to assess the patient?
Is it sustainable?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/25579572Wed, 01 Jul 2020 15:00:19 +0000cancerGRACEIn April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy had a candid discussion regarding telemedicine in the time of the current pandemic. In this time of social distancing and limiting clinic exposure, the sudden...
In this time of social distancing and limiting clinic exposure, the sudden need for telemedicine and web consults is perhaps changing the future of medicine on a faster pace than we have previously thought possible. In this three part series the doctors discuss a wide range of topics surrounding the use of telemedicine and potential challenges for providers and patients alike.

Does this new process create new helpful tools?
How does the informality of online visits affect the Doctor/Patient relationship?
Are there limitations to telemedicine - when and who is it good for, does it disrupt the ritualization of doctor/patient visits, and the ability to assess the patient?
Is it sustainable?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>736cancer,coronavirus,covid19,telehealthfalsefullhttps://www.spreaker.com/episode/case-based-panel-discussion-egfr-mutation-oligoprogression-in-brain-and-or-body-vs-worsening-progression-what-are-the-treatment-options--24525935Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.

In this series, the doctors discuss a series of cases related to EGFR Mutations - is there a place for chemotherapy and an EGFR inhibitor concurrently or sequentially in treatment decisions?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/24525935Wed, 24 Jun 2020 15:00:14 +0000cancerGRACEFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach. Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center. Dr. McCoach is...Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.

In this series, the doctors discuss a series of cases related to EGFR Mutations - is there a place for chemotherapy and an EGFR inhibitor concurrently or sequentially in treatment decisions?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>356cancergrace,cancerprogression,cancertreatment,egfr,lungcancer,nsclc,progression,treatmentfalsefullhttps://www.spreaker.com/episode/case-based-panel-discussion-3-1-egfr-mutation-chemotherapy-and-an-egfr-inhibitor-concurrently-or-sequentially-in-treatment-decisions--24525934Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.

In this series, the doctors discuss a series of cases related to EGFR Mutations - is there a place for chemotherapy and an EGFR inhibitor concurrently or sequentially in treatment decisions?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/24525934Wed, 24 Jun 2020 01:45:15 +0000cancerGRACEFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach. Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center. Dr. McCoach is...Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.

In this series, the doctors discuss a series of cases related to EGFR Mutations - is there a place for chemotherapy and an EGFR inhibitor concurrently or sequentially in treatment decisions?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>484cancer,cancergrace,chemotherapy,egfr,lungcancer,nsclc,treatmentfalsefullhttps://www.spreaker.com/episode/case-based-panel-discussion-2-2-patient-with-asymptomatic-brain-metastases-focal-radiation-before-alk-inhibitor-or-begin-with-alk-inhibitor--25979535Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.

Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.

The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is regarding a patient with ALK positive asymptomatic brain metastases. Is the standard approach of focal radiation before beginning ALK inhibitor appropriate, or do you begin with the ALK Inhibitor?]]>https://api.spreaker.com/episode/25979535Wed, 10 Jun 2020 15:00:15 +0000cancerGRACEFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center....Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.

Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.

The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is regarding a patient with ALK positive asymptomatic brain metastases. Is the standard approach of focal radiation before beginning ALK inhibitor appropriate, or do you begin with the ALK Inhibitor?]]>433alk,asymptomatic,brain,cancer,inhibitor,metastases,nsclc,radiationfalsefullhttps://www.spreaker.com/episode/case-based-panel-discussion-2-1-patient-with-good-performance-status-lung-adenocarcinoma-metastatic-disease-adrenal-lesion--25979534Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.

Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.

The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is surrounding what the approach for first line treatment would be for a patient with good performance status, lung adenocarcinoma, metastatic disease and adrenal lesions.]]>https://api.spreaker.com/episode/25979534Wed, 03 Jun 2020 15:00:08 +0000cancerGRACEFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center....Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.

Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.

The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is surrounding what the approach for first line treatment would be for a patient with good performance status, lung adenocarcinoma, metastatic disease and adrenal lesions.]]>623adenocarcinoma,adrenal,alk,cancer,disease,lesion,lung,metastatic,nsclcfalsefullhttps://www.spreaker.com/episode/case-based-panel-discussion-2-4-initial-brain-mets-progression-in-body-after-success-on-alk-inhibitor--25979530Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.

Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.

The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is regarding a patient with ALK positive asymptomatic brain metastases. Is the standard approach of focal radiation before beginning ALK inhibitor appropriate, or do you begin with the ALK Inhibitor?]]>https://api.spreaker.com/episode/25979530Wed, 27 May 2020 15:00:12 +0000cancerGRACEFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center....Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.

Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.

The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is regarding a patient with ALK positive asymptomatic brain metastases. Is the standard approach of focal radiation before beginning ALK inhibitor appropriate, or do you begin with the ALK Inhibitor?]]>447alk,brain,cancer,lung,metastases,metastasis,nsclc,progressionfalsefullhttps://www.spreaker.com/episode/case-based-panel-discussion-2-5-progression-after-alk-inhibitors-is-there-a-role-for-combination-therapies--25979532Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.

The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, they discuss progression after success on Alk inhibitors, and if there is a role for combination therapies like chemo/Avastin and immunotherapy.]]>https://api.spreaker.com/episode/25979532Wed, 20 May 2020 15:00:21 +0000cancerGRACEFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center....Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.

The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, they discuss progression after success on Alk inhibitors, and if there is a role for combination therapies like chemo/Avastin and immunotherapy.]]>714alk,cancer,cancergrace,inhibitors,lung,nsclc,therapiesfalsefullhttps://www.spreaker.com/episode/case-based-panel-discussion-2-3-developing-resistance-to-alk-inhibitors-areas-of-progression-after-years-of-success-treatment-approach--25979533Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.

Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.

The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, they discuss developing resistance to Alk inhibitors, treatment approaches and biopsies, and what are the next steps.]]>https://api.spreaker.com/episode/25979533Wed, 13 May 2020 15:00:20 +0000cancerGRACEFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center....Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.

Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.

The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, they discuss developing resistance to Alk inhibitors, treatment approaches and biopsies, and what are the next steps.]]>645alk,lungcancer,nsclc,progression,resistancefalsefullhttps://www.spreaker.com/episode/case-based-panel-discussion-2-7-clinical-significance-of-her2-mutation-how-does-a-positive-her2-mutation-effect-treatment-decisions-in-nsclc--25979536Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.

The doctors discuss a series of cases related to a diagnosis of NSCLC. In this video, the discussion is regarding a patient with a HER2 mutation, what is the clinical significance, and how does a positive HER2 mutation effect treatment decisions?]]>https://api.spreaker.com/episode/25979536Wed, 06 May 2020 15:00:21 +0000cancerGRACEFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center....Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.

The doctors discuss a series of cases related to a diagnosis of NSCLC. In this video, the discussion is regarding a patient with a HER2 mutation, what is the clinical significance, and how does a positive HER2 mutation effect treatment decisions?]]>439cancer,her2,lung,nsclc,treatmentfalsefullhttps://www.spreaker.com/episode/case-based-panel-discussion-2-6-alk-positive-and-high-pdl1-first-line-treatment-for-potentially-competing-targets--25979531Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.

Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.

The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is surrounding what the approach for first line treatment would be for a patient with good performance status, lung adenocarcinoma, metastatic disease and adrenal lesions.]]>https://api.spreaker.com/episode/25979531Wed, 29 Apr 2020 15:00:10 +0000cancerGRACEFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda. Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center....Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.

Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.

The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is surrounding what the approach for first line treatment would be for a patient with good performance status, lung adenocarcinoma, metastatic disease and adrenal lesions.]]>421alk,cancer,lung,nsclc,pdl1,targeted,therapyfalsefullhttps://www.spreaker.com/episode/case-based-panel-discussion-2019-3-egfr-uncommon-exon-20-mutation-suggested-treatments-targeted-therapy-and-clinica-trial--24906908Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.

In this series, the doctors discuss a series of cases related to an EGFR mutation. In this podcast, the discussion is regarding uncommon EXON 20 mutation, suggested treatments, targeted therapy and clinical trials.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/24906908Wed, 22 Apr 2020 15:00:21 +0000cancerGRACEFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach. Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center. Dr. McCoach is...Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.

In this series, the doctors discuss a series of cases related to an EGFR mutation. In this podcast, the discussion is regarding uncommon EXON 20 mutation, suggested treatments, targeted therapy and clinical trials.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>410cancer,cancergrace,egfr,exon20,lungfalsefullhttps://www.spreaker.com/episode/corona-virus-and-covid-19-key-questions-part-four-is-the-standard-care-changing-for-cancer-patients-because-of-the-pandemic--25652990
In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients.

In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic.

Part 1 - Should cancer patients get tested even if they show no symptoms?
Part 2 - Do cancer patients have a higher risk for Covid 19?
Part 3 - What preventive measures are trustworthy?
Part 4 - Is the standard of care changing for cancer patients because of the pandemic?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/25652990Sun, 19 Apr 2020 15:00:11 +0000cancerGRACEIn this podcast series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have a candid discussion regarding cancer and Covid 19. In this time of social distancing and limiting clinic exposure, the...
In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients.

In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic.

Part 1 - Should cancer patients get tested even if they show no symptoms?
Part 2 - Do cancer patients have a higher risk for Covid 19?
Part 3 - What preventive measures are trustworthy?
Part 4 - Is the standard of care changing for cancer patients because of the pandemic?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>764cancer,cancergrace,corona,covid,pandemic,treatment,virusfalsefullhttps://www.spreaker.com/episode/corona-virus-and-covid-19-key-questions-part-three-what-preventive-measures-are-trustworthy--25652806
In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients.

In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic.

Part 1 - Should cancer patients get tested even if they show no symptoms?
Part 2 - Do cancer patients have a higher risk for Covid 19?
Part 3 - What preventive measures are trustworthy?
Part 4 - Is the standard of care changing for cancer patients because of the pandemic?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/25652806Sat, 18 Apr 2020 15:00:04 +0000cancerGRACEIn this podcast series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have a candid discussion regarding cancer and Covid 19. In this time of social distancing and limiting clinic exposure, the...
In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients.

In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic.

Part 1 - Should cancer patients get tested even if they show no symptoms?
Part 2 - Do cancer patients have a higher risk for Covid 19?
Part 3 - What preventive measures are trustworthy?
Part 4 - Is the standard of care changing for cancer patients because of the pandemic?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>353cancer,cancergrace,corona,covid,covid19,pandemic,treatment,virusfalsefullhttps://www.spreaker.com/episode/corona-virus-and-covid-19-key-questions-part-two-do-cancer-patients-have-a-higher-risk--25652684
In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients.

In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic.

Part 1 - Should cancer patients get tested even if they show no symptoms?
Part 2 - Do cancer patients have a higher risk for Covid 19?
Part 3 - What preventive measures are trustworthy?
Part 4 - Is the standard of care changing for cancer patients because of the pandemic?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/25652684Fri, 17 Apr 2020 18:34:37 +0000cancerGRACEIn this podcast series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have a candid discussion regarding cancer and Covid 19. In this time of social distancing and limiting clinic exposure, the...
In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients.

In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic.

Part 1 - Should cancer patients get tested even if they show no symptoms?
Part 2 - Do cancer patients have a higher risk for Covid 19?
Part 3 - What preventive measures are trustworthy?
Part 4 - Is the standard of care changing for cancer patients because of the pandemic?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>417cancer,cancergrace,corona,covid,risk,treatmentfalsefullhttps://www.spreaker.com/episode/corona-virus-and-covid-19-key-questions-part-one-should-cancer-patients-get-tested--25622115
In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients.

In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic.

Part 1 - Should cancer patients get tested even if they show no symptoms?
Part 2 - Do cancer patients have a higher risk for Covid 19?
Part 3 - What preventive measures are trustworthy?
Part 4 - Is the standard of care changing for cancer patients because of the pandemic?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/25622115Thu, 16 Apr 2020 23:05:13 +0000cancerGRACEIn this video series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have a candid discussion regarding cancer and Covid 19. In this time of social distancing and limiting clinic exposure, the...
In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients.

In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic.

Part 1 - Should cancer patients get tested even if they show no symptoms?
Part 2 - Do cancer patients have a higher risk for Covid 19?
Part 3 - What preventive measures are trustworthy?
Part 4 - Is the standard of care changing for cancer patients because of the pandemic?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>483cancer,cancergrace,corona,covid19,treatment,virusfalsefullhttps://www.spreaker.com/episode/case-based-panel-discussion-2019-3-2-egfr-mutation-and-the-flaura-trial-is-there-a-difference-in-data-based-on-demographics--24906820Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.

In this series, the doctors discuss a series of cases related to EGFR Mutations. For EGFR mutations and the FLAURA trial, is there a difference in data based on demographics and how can that effect treatment decisions?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/24906820Wed, 15 Apr 2020 15:00:11 +0000cancerGRACEFor this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach. Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center. Dr. McCoach is...Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.

In this series, the doctors discuss a series of cases related to EGFR Mutations. For EGFR mutations and the FLAURA trial, is there a difference in data based on demographics and how can that effect treatment decisions?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>508cancer,cancergrace,egfr,flaura,lungfalsefullhttps://www.spreaker.com/episode/unresectable-nsclc-does-checkmate-227-s-suggestion-of-an-immunotherapy-combination-of-yervoy-and-opdivio-offer-another-treatment-option--23763629
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.

Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.

Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss Checkmate 227's suggestion of an immunotherapy combination of Yervoy (Ipilimumab) and Opdivo (Nivolumab) as another treatment option.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/23763629Wed, 08 Apr 2020 15:00:17 +0000cancerGRACEDr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and...
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.

Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.

Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss Checkmate 227's suggestion of an immunotherapy combination of Yervoy (Ipilimumab) and Opdivo (Nivolumab) as another treatment option.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>602227's,cancer,cancergrace,checkmate,immunotherapy,nsclc,opdivio,treatment,yervoyfalsefullhttps://www.spreaker.com/episode/unresectable-nsclc-tumor-mutational-burden-tmb-the-value-in-testing--23763420
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.

Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.

Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss Tumor Mutational Burden (TMB) and it's value in testing.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/23763420Wed, 01 Apr 2020 15:00:13 +0000cancerGRACEDr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and...
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.

Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.

Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss Tumor Mutational Burden (TMB) and it's value in testing.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>383burden,cancer,cancergrace,lung,mutational,nsclc,testing,(tmb),treatment,tumor,unresectablefalsefullhttps://www.spreaker.com/episode/unresctable-nsclc-concurrent-chemo-radiation-followed-by-immunotherapy-potential-pneumonitis-following-durvalumab-imfinzi--23762278Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.

Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.

Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss the standard treatment of chemotherapy and radiation followed by immunotherapy and the risk of pneumonitis.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/23762278Wed, 25 Mar 2020 15:00:01 +0000cancerGRACEDr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and...Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.

Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.

Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss the standard treatment of chemotherapy and radiation followed by immunotherapy and the risk of pneumonitis.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>332cancer,cancergrace,chemo,durvalumab,(imfinzi),immunotherapy,lung,nsclc,pneumonitis,radiation,treatmentfalsefullhttps://www.spreaker.com/episode/unresectable-nsclc-for-varying-patient-scenarios-fragile-patient-attrition-after-8-9-months-what-is-the-best-schedule-for-durvalumab--23762037
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.

Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.

Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss the standard treatment of chemotherapy and radiation followed by immunotherapy and the best schedule for Durvalumab (Imfinzi) in a variety of patient scenarios.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/23762037Wed, 18 Mar 2020 15:00:16 +0000cancerGRACEDr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and...
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.

Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.

Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss the standard treatment of chemotherapy and radiation followed by immunotherapy and the best schedule for Durvalumab (Imfinzi) in a variety of patient scenarios.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>554attrition,cancer,cancergrace,durvalumab,fragile,lung,nsclc,treatmentfalsefullhttps://www.spreaker.com/episode/unresectable-nsclc-treatment-standard-concurrent-chemo-rad-followed-by-immunotherapy-approach-for-patients-with-pdl1-score-of-0--23761705
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.

Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.

Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss the standard treatment of chemotherapy and radiation followed by immunotherapy and the approach for a patient with PDL1 score of 0. Would immunotherapy be beneficial?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>https://api.spreaker.com/episode/23761705Wed, 11 Mar 2020 18:50:55 +0000cancerGRACEDr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and...
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.

Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.

Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss the standard treatment of chemotherapy and radiation followed by immunotherapy and the approach for a patient with PDL1 score of 0. Would immunotherapy be beneficial?

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.]]>435cancer,cancergrace,chemo,concurrent,immunotherapy,lung,nsclc,pdl1,radiation,treatmentfalsefullhttps://www.spreaker.com/episode/unresectable-nsclc-does-timing-of-treatment-make-a-difference-in-response--23219770
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.

Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.

Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss a patient with unresectable NSCLC, and whether the timing of treatment makes a difference in their response.]]>https://api.spreaker.com/episode/23219770Wed, 04 Mar 2020 16:00:18 +0000cancerGRACEDr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and...
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.

Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.

Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss a patient with unresectable NSCLC, and whether the timing of treatment makes a difference in their response.]]>666cancer,cancergrace,lung,nsclc,patient,treatmentfalsefullhttps://www.spreaker.com/episode/unresectable-nsclc-in-a-frail-patient-with-competing-risks-is-the-standard-treatment-the-best-approach--23195571
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.

Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.

Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss a stage 3 frail patient with unresectable NSCLC, Unresectable NSCLC with competing risks, and if the standard treatment is the best approach.]]>https://api.spreaker.com/episode/23195571Wed, 26 Feb 2020 16:00:14 +0000cancerGRACEDr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and...
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.

Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.

Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss a stage 3 frail patient with unresectable NSCLC, Unresectable NSCLC with competing risks, and if the standard treatment is the best approach.]]>733approach,best,cancer,cancergrace,competing,frail,lung,nsclc,patient,risks,standard,treatment,unresectablefalsefullhttps://www.spreaker.com/episode/unresectable-nsclc-should-molecular-tests-be-considered-and-would-outcome-effect-treatment-decisions--22938957
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.

Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.

Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss the option of molecular testing for stage 3 NSCLC, and whether or not the outcome effects treatment decisions.]]>https://api.spreaker.com/episode/22938957Wed, 19 Feb 2020 16:00:14 +0000cancerGRACEDr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC . Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and...
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.

Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.

Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss the option of molecular testing for stage 3 NSCLC, and whether or not the outcome effects treatment decisions.]]>738cancer,lungcancer,molecular,nsclc,testingfalsefull